UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 26, ~~2020~~2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 0-27078

HENRY SCHEIN, INC.

(Exact name of registrant as specified in its charter)

Delaware	11-3136595
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

135 Duryea Road

Melville, New York

(Address of principal executive offices)

11747

(Zip Code)

(631) 843-5500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.01 per share	HSIC	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒

No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒

No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒		Accelerated filer ☐
Non-accelerated filer ☐		Smaller reporting company ☐
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐

No ☒

As of ~~October~~July 26, ~~2020~~2021, there were ~~142,776,158~~139,693,210 shares of the registrant’s common stock outstanding.

HENRY SCHEIN, INC.

INDEX


PART I. FINANCIAL INFORMATION
				Page
ITEM 1.	Consolidated Financial Statements:

		Balance Sheets as of ~~September~~June 26, ~~2020~~2021 and December ~~28, 2019~~26, 2020		3

		Statements of Income for the three and ~~nine~~six months ended
			~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020	4

		Statements of Comprehensive Income for the three and ~~nine~~six months ended
			~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020	5

		Statement of Changes in Stockholders' Equity for the three months ended
			~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020	6

		Statement of Changes in Stockholders' Equity for the ~~nine~~six months ended
			~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020	7

		Statements of Cash Flows for the ~~nine~~six months ended
			~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020	8

		Notes to Consolidated Financial Statements		9
			Note 1 – Basis of Presentation	9
			Note 2 – ~~Discontinued Operations~~	11
			~~Note 3 –~~ Critical Accounting Policies, Accounting Pronouncements Adopted
			and Recently Issued Accounting Standards	1410
			Note 3 – Revenue from Contracts with Customers	11
			Note 4 – ~~Revenue from Contracts with Customers~~Segment Data	1512
			Note 5 – ~~Segment Data~~Debt	13
			Note 6 – Leases	16
			Note 67 – ~~Debt~~Redeemable Noncontrolling Interests	1718
			Note 78 – ~~Leases~~Comprehensive Income	18
			Note 9 – Fair Value Measurements	20
			Note 810 – ~~Redeemable Noncontrolling Interests~~Business Acquisitions	22
			Note 911 – ~~Comprehensive Income~~Plans of Restructuring	23
			Note 1012 – ~~Fair Value Measurements~~Earnings Per Share	24
			Note 1113 – ~~Business Acquisitions~~Income Taxes	25
			Note 14 – Derivatives and Hedging Activities	26
			Note 1215 – ~~Plans of Restructuring~~Stock-Based Compensation	27
			Note 1316 – ~~Earnings Per Share~~	28
			~~Note 14 – Income Taxes~~Supplemental Cash Flow Information	29
			Note 1517 – ~~Derivatives and Hedging Activities~~Legal Proceedings	30
			Note ~~16 – Stock-Based Compensation~~	31
			~~Note 17 – Supplemental Cash Flow Information~~	33
			~~Note~~ 18 ~~– Legal Proceedings~~	33
			~~Note 19~~ – Related Party Transactions	3732

ITEM 2.	Management's Discussion and Analysis of
			Financial Condition and Results of Operations	3834

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk			5853

ITEM 4.	Controls and Procedures			5954

PART II. OTHER INFORMATION

ITEM 1.	Legal Proceedings			6055

ITEM 1A.	Risk Factors			6055

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds			6355

~~ITEM 5.~~	~~Other Information~~			63

ITEM 6.	Exhibits			6456

	Signature			6557

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

HENRY SCHEIN, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

				September 26,		December 28,					June 26,		December 26,
				2020		2019					2021		2020
				(unaudited)							(unaudited)
ASSETS	ASSETS							ASSETS
Current assets:	Current assets:							Current assets:
	Cash and cash equivalents			$	533,495	$	106,097	Cash and cash equivalents			$	167,228	$	421,185
	Accounts receivable, net of reserves of $86,371 and $60,002				1,407,676		1,246,246	Accounts receivable, net of reserves of $81,113 and $88,030				1,356,881		1,424,787
	Inventories, net				1,463,434		1,428,799	Inventories, net				1,688,210		1,512,499
	Prepaid expenses and other				464,645		445,360	Prepaid expenses and other				529,929		432,944
			Total current assets		3,869,250		3,226,502			Total current assets		3,742,248		3,791,415
Property and equipment, net	Property and equipment, net				334,954		329,645	Property and equipment, net				358,224		342,004
Operating lease right-of-use assets, net					249,895		231,662
Operating lease right-of-use assets								Operating lease right-of-use assets				301,440		288,847
Goodwill	Goodwill				2,488,962		2,462,495	Goodwill				2,722,974		2,504,392
Other intangibles, net	Other intangibles, net				510,395		572,878	Other intangibles, net				604,515		479,429
Investments and other	Investments and other				356,439		327,919	Investments and other				394,665		366,445
			Total assets	$	7,809,895	$	7,151,101			Total assets	$	8,124,066	$	7,772,532

LIABILITIES AND STOCKHOLDERS' EQUITY	LIABILITIES AND STOCKHOLDERS' EQUITY							LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:	Current liabilities:							Current liabilities:
	Accounts payable			$	1,006,958	$	880,266	Accounts payable			$	903,859	$	1,005,655
	Bank credit lines				507,372		23,975	Bank credit lines				72,105		73,366
	Current maturities of long-term debt				110,015		109,849	Current maturities of long-term debt				9,839		109,836
	Operating lease liabilities				62,914		65,349	Operating lease liabilities				75,008		64,716
	Accrued expenses:							Accrued expenses:
		Payroll and related			250,365		265,206		Payroll and related			313,892		295,329
		Taxes			138,196		165,171		Taxes			156,176		138,671
		Other			527,987		528,553		Other			562,762		595,529
			Total current liabilities		2,603,807		2,038,369			Total current liabilities		2,093,641		2,283,102
Long-term debt	Long-term debt				515,357		622,908	Long-term debt				706,487		515,773
Deferred income taxes	Deferred income taxes				32,408		64,989	Deferred income taxes				46,528		30,065
Operating lease liabilities	Operating lease liabilities				200,611		176,267	Operating lease liabilities				243,232		238,727
Other liabilities	Other liabilities				370,745		331,173	Other liabilities				423,416		392,781
			Total liabilities		3,722,928		3,233,706			Total liabilities		3,513,304		3,460,448

Redeemable noncontrolling interests	Redeemable noncontrolling interests				294,700		287,258	Redeemable noncontrolling interests				604,081		327,699
Commitments and contingencies	Commitments and contingencies							Commitments and contingencies

Stockholders' equity:	Stockholders' equity:							Stockholders' equity:
	Preferred stock, $.01 par value, 1,000,000 shares authorized,							Preferred stock, $0.01 par value, 1,000,000 shares authorized,
		none outstanding			0		0		NaN outstanding			0		0
	Common stock, $.01 par value, 480,000,000 shares authorized,							Common stock, $0.01 par value, 480,000,000 shares authorized,
		142,456,318 outstanding on September 26, 2020 and							139,780,841 outstanding on June 26, 2021 and
		143,353,459 outstanding on December 28, 2019			1,425		1,434		142,462,571 outstanding on December 26, 2020			1,398		1,425
	Additional paid-in capital				11,044		47,768	Additional paid-in capital				0		0
	Retained earnings				3,314,136		3,116,215	Retained earnings				3,465,647		3,454,831
	Accumulated other comprehensive loss				(171,332)		(167,373)	Accumulated other comprehensive loss				(106,779)		(108,084)
		Total Henry Schein, Inc. stockholders' equity			3,155,273		2,998,044		Total Henry Schein, Inc. stockholders' equity			3,360,266		3,348,172
	Noncontrolling interests				636,994		632,093	Noncontrolling interests				646,415		636,213
			Total stockholders' equity		3,792,267		3,630,137			Total stockholders' equity		4,006,681		3,984,385
		Total liabilities, redeemable noncontrolling interests and stockholders' equity		$	7,809,895	$	7,151,101		Total liabilities, redeemable noncontrolling interests and stockholders' equity		$	8,124,066	$	7,772,532

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENTS OF INCOME~~

~~(in thousands, except per share data)~~

~~(unaudited)~~

CONSOLIDATED STATEMENTS OF INCOME

Three Months Ended

Nine Months Ended

September 26,

September 28,

September 26,

September 28,

2020

2019

2020

2019

Net sales

$
2,840,146

$
2,508,767

$
6,953,416

$
7,316,862
Cost of sales

2,085,847

1,747,600

4,998,784

5,036,574

Gross profit

754,299

761,167

1,954,632

2,280,288
Operating expenses:

Selling, general and administrative

559,636

574,771

1,572,816

1,742,597

Restructuring costs (credits)

6,992

(802)

27,713

15,764

Operating income

187,671

187,198

354,103

521,927
Other income (expense):

Interest income

2,294

3,943

7,481

12,368

Interest expense

(11,111)

(12,373)

(29,409)

(41,459)

Other, net

(1,699)

(177)

(2,210)

(2,012)

Income from continuing operations before taxes,

equity in earnings of affiliates and noncontrolling interests

177,155

178,591

329,965

490,824
Income taxes

(29,005)

(41,964)

(65,965)

(117,326)
Equity in earnings of affiliates

3,663

6,585

7,808

14,771
Net income from continuing operations

151,813

143,212

271,808

388,269
Income (loss) from discontinued operations, net of tax

(29)

5,641

274

(5,576)
Net income

151,784

148,853

272,082

382,693

Less: Net income attributable to noncontrolling interests

(10,087)

(8,296)

(10,921)

(18,187)

Plus: Net loss attributable to noncontrolling interests

from discontinued operations

0

0

0

366
Net income attributable to Henry Schein, Inc.

$
141,697

$
140,557

$
261,161

$
364,872
Amounts attributable to Henry Schein Inc.:

Continuing operations

$
141,726

$
134,916

$
260,887

$
370,082
Discontinued operations

(29)

5,641

274

(5,210)
Net income attributable to Henry Schein, Inc.

$
141,697

$
140,557

$
261,161

$
364,872

Earnings per share from continuing operations attributable to Henry Schein, Inc.:

Basic

$
1.00

$
0.92

$
1.83

$
2.49

Diluted

$
0.99

$
0.91

$
1.82

$
2.47

Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:

Basic

$
0

$
0.04

$
0

$
(0.04)

Diluted

$
0

$
0.04

$
0

$
(0.04)

Earnings per share attributable to Henry Schein, Inc.:

Basic

$
1.00

$
0.96

$
1.83

$
2.46

Diluted

$
0.99

$
0.95

$
1.82

$
2.43

Weighted-average common shares outstanding:

Basic

142,362

147,136

142,553

148,603

Diluted

143,091
��

148,575

143,308

149,920

(in thousands, except per share data)

(unaudited)

				Three Months Ended				Six Months Ended
				June 26,		June 27,		June 26,		June 27,
				2021		2020		2021		2020

Net sales				$	2,967,223	$	1,684,399	$	5,892,184	$	4,113,270
Cost of sales					2,077,472		1,230,133		4,111,582		2,912,990
		Gross profit			889,751		454,266		1,780,602		1,200,280
Operating expenses:
	Selling, general and administrative				678,801		445,765		1,336,793		1,013,127
	Restructuring costs				604		15,934		3,535		20,721
		Operating income (loss)			210,346		(7,433)		440,274		166,432
Other income (expense):
	Interest income				1,357		1,997		3,340		5,187
	Interest expense				(6,376)		(10,486)		(12,861)		(18,298)
	Other, net				354		(291)		663		(511)
		Income (loss) from continuing operations before taxes,
			equity in earnings of affiliates and noncontrolling interests		205,681		(16,213)		431,416		152,810
Income tax benefit (expense)					(48,027)		950		(104,712)		(36,960)
Equity in earnings of affiliates					6,323		1,411		12,201		4,145
Net income (loss) from continuing operations					163,977		(13,852)		338,905		119,995
Income from discontinued operations, net of tax					0		585		0		303
Net income (loss)					163,977		(13,267)		338,905		120,298
	Less: Net (income) loss attributable to noncontrolling interests				(8,261)		2,470		(17,192)		(834)
	Plus: Net loss attributable to noncontrolling interests
			from discontinued operations		0		0		0		0
Net income (loss) attributable to Henry Schein, Inc.				$	155,716	$	(10,797)	$	321,713	$	119,464
Amounts attributable to Henry Schein Inc.:
Continuing operations				$	155,716	$	(11,382)	$	321,713	$	119,161
Discontinued operations					0		585		0		303
Net income (loss) attributable to Henry Schein, Inc.				$	155,716	$	(10,797)	$	321,713	$	119,464

Earnings (loss) per share from continuing operations attributable to Henry Schein, Inc.:

	Basic			$	1.11	$	(0.08)	$	2.28	$	0.84
	Diluted			$	1.10	$	(0.08)	$	2.26	$	0.84

Earnings per share from discontinued operations attributable to Henry Schein, Inc.:

	Basic			$	0	$	0	$	0	$	0
	Diluted			$	0	$	0	$	0	$	0

Earnings (loss) per share attributable to Henry Schein, Inc.:

	Basic			$	1.11	$	(0.08)	$	2.28	$	0.84
	Diluted			$	1.10	$	(0.08)	$	2.26	$	0.84

Weighted-average common shares outstanding:
	Basic				140,358		142,350		141,316		142,654
	Diluted				141,657		142,350		142,538		142,654

See accompanying notes.

Table of Contents

~~HENRY SCHEIN, INC.~~

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)

				Three Months Ended				Nine Months Ended							Three Months Ended				Six Months Ended
				September 26,		September 28,		September 26,		September 28,					June 26,		June 27,		June 26,		June 27,
				2020		2019		2020		2019					2021		2020		2021		2020

Net income				$	151,784	$	148,853	$	272,082	$	382,693
Net income (loss)												Net income (loss)			$	163,977	$	(13,267)	$	338,905	$	120,298

Other comprehensive income (loss), net of tax:	Other comprehensive income (loss), net of tax:											Other comprehensive income (loss), net of tax:
	Foreign currency translation gain (loss)				37,588		(60,635)		(17,316)		(43,926)	Foreign currency translation gain (loss)				38,138		34,408		(343)		(54,904)

	Unrealized gain (loss) from foreign currency hedging											Unrealized gain (loss) from foreign currency hedging
		activities			(7,697)		(1,263)		2,457		(1,586)		activities			(1,751)		(4,989)		1,610		10,154

	Unrealized investment gain (loss)				2		2		(5)		8	Unrealized investment gain (loss)				3		2		(3)		(7)

	Pension adjustment gain (loss)				(338)		400		161		832	Pension adjustment gain (loss)				35		(225)		842		499

Other comprehensive income (loss), net of tax	Other comprehensive income (loss), net of tax				29,555		(61,496)		(14,703)		(44,672)	Other comprehensive income (loss), net of tax				36,425		29,196		2,106		(44,258)
Comprehensive income	Comprehensive income				181,339		87,357		257,379		338,021	Comprehensive income				200,402		15,929		341,011		76,040
	Comprehensive income attributable to noncontrolling											Comprehensive income attributable to noncontrolling
	interests:											interests:
		Net income			(10,087)		(8,296)		(10,921)		(17,821)		Net (income) loss			(8,261)		2,470		(17,192)		(834)
		Foreign currency translation (gain) loss			(1,636)		6,014		10,744		4,609		Foreign currency translation (gain) loss			(6,899)		(799)		(801)		12,380
			Comprehensive income attributable to noncontrolling											Comprehensive (income) loss attributable to noncontrolling
			interests		(11,723)		(2,282)		(177)		(13,212)			interests		(15,160)		1,671		(17,993)		11,546

Comprehensive income attributable to Henry Schein, Inc.	Comprehensive income attributable to Henry Schein, Inc.			$	169,616	$	85,075	$	257,202	$	324,809	Comprehensive income attributable to Henry Schein, Inc.			$	185,242	$	17,600	$	323,018	$	87,586

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except share and per share data)

(unaudited)

									Accumulated
		Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, March 27, 2021		141,310,113	$	1,413	$	0	$	3,493,060	$	(136,305)	$	638,562	$	3,996,730
Net income (excluding $6,980 attributable to Redeemable
	noncontrolling interests from continuing operations)	-		0		0		155,716		0		1,281		156,997
Foreign currency translation gain (excluding gain of $6,743
	attributable to Redeemable noncontrolling interests)	-		0		0		0		31,239		156		31,395
Unrealized loss from foreign currency hedging activities,
	net of tax benefit of $687	-		0		0		0		(1,751)		0		(1,751)
Unrealized investment gain, net of tax of $1		-		0		0		0		3		0		3
Pension adjustment gain, net of tax benefit of $38		-		0		0		0		35		0		35
Dividends paid		-		0		0		0		0		(77)		(77)
Change in fair value of redeemable securities		-		0		(87,188)		0		0		0		(87,188)
Initial noncontrolling interests and adjustments related to
	business acquisitions	-		0		0		0		0		6,493		6,493
Repurchase and retirement of common stock		(1,542,315)		(15)		(14,992)		(97,545)		0		0		(112,552)
Stock-based compensation expense		17,916		0		17,364		0		0		0		17,364
Shares withheld for payroll taxes		(4,873)		0		(369)		0		0		0		(369)
Settlement of stock-based compensation awards		-		0		(399)		0		0		0		(399)
Transfer of charges in excess of capital		-		0		85,584		(85,584)		0		0		0
Balance, June 26, 2021		139,780,841	$	1,398	$	0	$	3,465,647	$	(106,779)	$	646,415	$	4,006,681

									Accumulated
		Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, March 28, 2020		142,433,360	$	1,424	$	17,565	$	3,183,236	$	(227,648)	$	631,215	$	3,605,792
Net loss (excluding loss of $1,678 attributable to Redeemable
	noncontrolling interests from continuing operations)	-		0		0		(10,797)		0		(792)		(11,589)
Foreign currency translation gain (excluding gain of $751
	attributable to Redeemable noncontrolling interests)	-		0		0		0		33,609		48		33,657
Unrealized loss from foreign currency hedging activities,
	net of tax benefit of $1,744	-		0		0		0		(4,989)		0		(4,989)
Unrealized investment gain, net of tax of $1		-		0		0		0		2		0		2
Pension adjustment loss, net of tax benefit of $125		-		0		0		0		(225)		0		(225)
Dividends paid		-		0		0		0		0		(8)		(8)
Purchase of noncontrolling interests		-		0		0		0		0		(9)		(9)
Change in fair value of redeemable securities		-		0		(7,489)		0		0		0		(7,489)
Initial noncontrolling interests and adjustments related to
	business acquisitions	-		0		0		0		0		4		4
Stock-based compensation expense		7,033		0		5,156		0		0		0		5,156
Shares withheld for payroll taxes		(2,266)		0		(132)		0		0		0		(132)
Settlement of stock-based compensation awards		-		0		(273)		0		0		0		(273)
Separation of Animal Health business		-		0		1,648		0		0		0		1,648
Balance, June 27, 2020		142,438,127	$	1,424	$	16,475	$	3,172,439	$	(199,251)	$	630,458	$	3,621,545

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except share and per share data)

(unaudited)

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, June 27, 2020
142,438,127
$
1,424
$
16,475
$
3,172,439
$
(199,251)
$
630,458
$
3,621,545
Net income (excluding $6,092 attributable to Redeemable

noncontrolling interests from continuing operations)
-

0

0

141,697

0

3,995

145,692
Foreign currency translation gain (excluding gain of $1,277

attributable to Redeemable noncontrolling interests)
-

0

0

0

35,952

359

36,311
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $2,793
-

0

0

0

(7,697)

0

(7,697)
Unrealized investment gain, net of tax of $0
-

0

0

0

2

0

2
Pension adjustment loss, net of tax benefit of $133
-

0

0

0

(338)

0

(338)
Dividends paid
-

0

0

0

0

(309)

(309)
Change in fair value of redeemable securities
-

0

(10,724)

0

0

0

(10,724)
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

2,491

2,491
Stock-based compensation expense
21,113

0

5,710

0

0

0

5,710
Shares withheld for payroll taxes
(2,922)

1

(194)

0

0

0

(193)
Settlement of stock-based compensation awards
0

0

(223)

0

0

0

(223)
Balance, September 26, 2020
142,456,318
$
1,425
$
11,044
$
3,314,136
$
(171,332)
$
636,994
$
3,792,267

									Accumulated
		Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, December 26, 2020		142,462,571	$	1,425	$	0	$	3,454,831	$	(108,084)	$	636,213	$	3,984,385
Net income (excluding $14,033 attributable to Redeemable
	noncontrolling interests from continuing operations)	-		0		0		321,713		0		3,159		324,872
Foreign currency translation gain (loss) (excluding gain of $570
	attributable to Redeemable noncontrolling interests)	-		0		0		0		(1,144)		231		(913)
Unrealized gain from foreign currency hedging activities,
	net of tax of $647	-		0		0		0		1,610		0		1,610
Unrealized investment loss, net of tax benefit of $1		-		0		0		0		(3)		0		(3)
Pension adjustment gain, net of tax of $181		-		0		0		0		842		0		842
Dividends paid		-		0		0		0		0		(154)		(154)
Change in fair value of redeemable securities		-		0		(132,708)		0		0		0		(132,708)
Initial noncontrolling interests and adjustments related to
	business acquisitions	-		0		0		0		0		6,966		6,966
Repurchase and retirement of common stock		(2,867,557)		(29)		(27,241)		(173,941)		0		0		(201,211)
Stock-based compensation expense		299,561		3		30,151		0		0		0		30,154
Shares withheld for payroll taxes		(113,734)		(1)		(7,546)		0		0		0		(7,547)
Settlement of stock-based compensation awards		0		0		388		0		0		0		388
Transfer of charges in excess of capital		-		0		136,956		(136,956)		0		0		0
Balance, June 26, 2021		139,780,841	$	1,398	$	0	$	3,465,647	$	(106,779)	$	646,415	$	4,006,681

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, June 29, 2019
147,823,846
$
1,478
$
65,356
$
2,900,387
$
(139,944)
$
618,937
$
3,446,214
Net income (excluding $4,105 attributable to Redeemable

noncontrolling interests from continuing operations)
-

0

0

140,557

0

4,191

144,748
Foreign currency translation loss (excluding loss of $5,748

attributable to Redeemable noncontrolling interests)
-

0

0

0

(54,621)

(266)

(54,887)
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $422
-

0

0

0

(1,263)

0

(1,263)
Unrealized investment gain, net of tax of $1
-

0

0

0

2

0

2
Pension adjustment gain, net of tax of $185
-

0

0

0

400

0

400
Dividends paid
-

0

0

0

0

(84)

(84)
Other adjustments
-

0

1

0

0

0

1
Change in fair value of redeemable securities
-

0

1,667

0

0

0

1,667
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

7,004

7,004
Repurchase and retirement of common stock
(1,571,909)

(15)

(15,109)

(83,094)

0

0

(98,218)
Stock-based compensation expense
6,028

0

13,338

0

0

0

13,338
Shares withheld for payroll taxes
(3,101)

0

(199)

0

0

0

(199)
Settlement of stock-based compensation awards
0

0

(85)

0

0

0

(85)
Separation of Animal Health business
-

0

672

0

0

0

672
Balance, September 28, 2019
146,254,864
$
1,463
$
65,641
$
2,957,850
$
(195,426)
$
629,782
$
3,459,310

~~See accompanying notes.~~

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY~~

~~(in thousands, except share and per share data)~~

~~(unaudited)~~

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, December 28, 2019
143,353,459
$
1,434
$
47,768
$
3,116,215
$
(167,373)
$
632,093
$
3,630,137
Cumulative impact of adopting new accounting standards
-

0

0

(412)

0

0

(412)
Net income (excluding $7,253 attributable to Redeemable

noncontrolling interests from continuing operations)
-

0

0

261,161

0

3,668

264,829
Foreign currency translation gain (loss) (excluding loss of $10,999

attributable to Redeemable noncontrolling interests)
-

0

0

0

(6,572)

255

(6,317)
Unrealized gain from foreign currency hedging activities,

net of tax of $553
-

0

0

0

2,457

0

2,457
Unrealized investment loss, net of tax benefit of $1
-

0

0

0

(5)

0

(5)
Pension adjustment gain, net of tax of $66
-

0

0

0

161

0

161
Dividends paid
-

0

0

0

0

(816)

(816)
Purchase of noncontrolling interests
-

0

(1,597)

0

0

(701)

(2,298)
Change in fair value of redeemable securities
-

0

(5,141)

0

0

0

(5,141)
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

2,495

2,495
Repurchase and retirement of common stock
(1,200,000)

(12)

(10,949)

(62,828)

0

0

(73,789)
Stock-based compensation expense (credit)
535,556

5

(6,653)

0

0

0

(6,648)
Shares withheld for payroll taxes
(232,697)

(2)

(14,197)

0

0

0

(14,199)
Settlement of stock-based compensation awards
0

0

164

0

0

0

164
Separation of Animal Health business
-

0

1,649

0

0

0

1,649
Balance, September 26, 2020
142,456,318
$
1,425
$
11,044
$
3,314,136
$
(171,332)
$
636,994
$
3,792,267

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, December 29, 2018
151,401,668
$
1,514
$
0
$
3,208,589
$
(248,771)
$
580,456
$
3,541,788
Cumulative impact of adopting new accounting standards
-

0

0

(274)

0

0

(274)
Net income (excluding $10,618 attributable to Redeemable

noncontrolling interests from continuing operations

and ($366) from discontinued operations)
-

0

0

364,872

0

7,569

372,441
Foreign currency translation loss (excluding loss of $4,912

attributable to Redeemable noncontrolling interests

and $592 gain from discontinued operations)
-

0

0

0

(39,317)

(289)

(39,606)
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $451
-

0

0

0

(1,586)

0

(1,586)
Unrealized investment gain, net of tax of $2
-

0

0

0

8

0

8
Pension adjustment gain, net of tax of $314
-

0

0

0

832

0

832
Dividends paid
-

0

0

0

0

(299)

(299)
Other adjustments
-

0

(3)

0

0

0

(3)
Change in fair value of redeemable securities
-

0

5,867

0

0

0

5,867
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

42,345

42,345
Adjustment for Animal Health Spin-off
87,629

1

0

0

0

0

1
Repurchase and retirement of common stock
(5,277,256)

(52)

(51,312)

(273,636)

0

0

(325,000)
Stock issued upon exercise of stock options
2,526

0

34

0

0

0

34
Stock-based compensation expense
218,563

2

33,433

0

0

0

33,435
Shares withheld for payroll taxes
(178,266)

(2)

(10,765)

0

0

0

(10,767)
Settlement of stock-based compensation awards
0

0

303

0

0

0

303
Share Sale related to Animal Health business
-

0

361,090

0

0

0

361,090
Separation of Animal Health business
-

0

(71,549)

(543,158)

93,408

0

(521,299)
Transfer of charges in excess of capital
-

0

(201,457)

201,457

0

0

0
Balance, September 28, 2019
146,254,864
$
1,463
$
65,641
$
2,957,850
$
(195,426)
$
629,782
$
3,459,310

									Accumulated
		Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, December 28, 2019		143,353,459	$	1,434	$	47,768	$	3,116,215	$	(167,373)	$	632,093	$	3,630,137
Cumulative impact of adopting new accounting standards		-		0		0		(412)		0		0		(412)
Net income (excluding $1,161 attributable to Redeemable
	noncontrolling interests from continuing operations)	-		0		0		119,464		0		(327)		119,137
Foreign currency translation loss (excluding loss of $12,276
	attributable to Redeemable noncontrolling interests)	-		0		0		0		(42,524)		(104)		(42,628)
Unrealized gain from foreign currency hedging activities,
	net of tax of $3,346	-		0		0		0		10,154		0		10,154
Unrealized investment loss, net of tax benefit of $1		-		0		0		0		(7)		0		(7)
Pension adjustment gain, net of tax of $199		-		0		0		0		499		0		499
Dividends paid		-		0		0		0		0		(507)		(507)
Purchase of noncontrolling interests		-		0		(1,597)		0		0		(701)		(2,298)
Change in fair value of redeemable securities		-		0		5,583		0		0		0		5,583
Initial noncontrolling interests and adjustments related to
	business acquisitions	-		0		0		0		0		4		4
Repurchase and retirement of common stock		(1,200,000)		(12)		(10,949)		(62,828)		0		0		(73,789)
Stock-based compensation expense (credit)		514,443		5		(12,363)		0		0		0		(12,358)
Shares withheld for payroll taxes		(229,775)		(3)		(14,003)		0		0		0		(14,006)
Settlement of stock-based compensation awards		0		0		387		0		0		0		387
Separation of Animal Health business		-		0		1,649		0		0		0		1,649
Balance, June 27, 2020		142,438,127	$	1,424	$	16,475	$	3,172,439	$	(199,251)	$	630,458	$	3,621,545

See accompanying notes.

Table of Contents

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~(in thousands, except per share data)~~

~~(unaudited)~~

September 26,

September 28,

2020

2019
Cash flows from operating activities:

Net income

$
272,082

$
382,693

Income (loss) from discontinued operations

274

(5,576)

Income from continuing operations

271,808

388,269

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

140,664

136,210

Stock-based compensation (credit) expense

(6,648)

33,110

Provision for losses on trade and other accounts receivable

34,590

7,576

Benefit from deferred income taxes

(48,193)

(3,468)

Equity in earnings of affiliates

(7,808)

(14,771)

Distributions from equity affiliates

10,053

67,913

Changes in unrecognized tax benefits

(18,365)

3,535

Other

4,794

(2,122)

Changes in operating assets and liabilities, net of acquisitions:

Accounts receivable

(199,858)

(115,384)

Inventories

(25,830)

75,093

Other current assets

(51,746)

(70,348)

Accounts payable and accrued expenses

144,953

19,567
Net cash provided by operating activities from continuing operations

248,414

525,180
Net cash provided by (used in) operating activities from discontinued operations

648

(163,653)
Net cash provided by operating activities

249,062

361,527

Cash flows from investing activities:

Purchases of fixed assets

(37,799)

(48,956)

Payments related to equity investments and business

acquisitions, net of cash acquired

(52,208)

(657,093)

Proceeds from sale of equity investment

12,000

10,500

Proceeds from (repayments to) loan to affiliate

(1,451)

16,448

Other

(14,498)

(12,248)
Net cash used in investing activities from continuing operations

(93,956)

(691,349)
Net cash used in investing activities from discontinued operations

0

(2,064)
Net cash used in investing activities

(93,956)

(693,413)

Cash flows from financing activities:

Net change in bank borrowings

484,139

(843,846)

Proceeds from issuance of long-term debt

501,421

741

Principal payments for long-term debt

(610,457)

(10,252)

Debt issuance costs

(3,683)

(391)

Debt extinguishment costs

(401)

0

Proceeds from issuance of stock upon exercise of stock options

0

34

Payments for repurchases of common stock

(73,789)

(325,000)

Payments for taxes related to shares withheld for employee taxes

(14,007)

(10,751)

Distribution received related to Animal Health Spin-off

0

1,120,000

Proceeds related to Animal Health Share Sale

0

361,090

Proceeds from (distributions to) noncontrolling shareholders

(3,995)

53,429

Acquisitions of noncontrolling interests in subsidiaries

(14,934)

(2,358)

Proceeds from (payments to) Henry Schein Animal Health Business

139

(166,557)
Net cash provided by financing activities from continuing operations

264,433

176,139
Net cash provided by (used in) financing activities from discontinued operations

(648)

144,633
Net cash provided by financing activities

263,785

320,772
Effect of exchange rate changes on cash and cash equivalents from continuing operations

8,507

8,401
Effect of exchange rate changes on cash and cash equivalents from discontinued operations

0

(2,240)
Net change in cash and cash equivalents from continuing operations

427,398

18,371
Net change in cash and cash equivalents from discontinued operations

0

(23,324)
Cash and cash equivalents, beginning of period

106,097

56,885
Cash and cash equivalents, end of period

$
533,495

$
75,256

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

					Six Months Ended
					June 26,		June 27,
					2021		2020
Cash flows from operating activities:
	Net income				$	338,905	$	120,298
	Income from discontinued operations					0		303
	Income from continuing operations					338,905		119,995
	Adjustments to reconcile net income to net cash provided by (used in) operating activities:
			Depreciation and amortization			99,278		93,946
			Impairment charge on intangible assets			0		2,149
			Stock-based compensation expense (credit)			30,154		(12,358)
			Provision for (benefit from) losses on trade and other accounts receivable			(4,072)		28,758
			Provision (benefit from) for deferred income taxes			5,705		(32,871)
			Equity in earnings of affiliates			(12,201)		(4,145)
			Distributions from equity affiliates			10,747		4,220
			Changes in unrecognized tax benefits			(6,286)		1,380
			Other			3,429		227
			Changes in operating assets and liabilities, net of acquisitions:
				Accounts receivable		101,619		99,672
				Inventories		(123,758)		13,700
				Other current assets		(85,979)		(188,616)
				Accounts payable and accrued expenses		(135,815)		(138,900)
Net cash provided by (used in) operating activities from continuing operations						221,726		(12,843)
Net cash provided by operating activities from discontinued operations						0		573
Net cash provided by (used in) operating activities						221,726		(12,270)

Cash flows from investing activities:
	Purchases of fixed assets					(31,812)		(30,588)
	Payments related to equity investments and business
		acquisitions, net of cash acquired				(295,652)		(37,725)
	Proceeds from sale of equity investment					0		12,000
	Payments for loan to affiliate					(2,021)		(1,729)
	Other					(11,634)		(11,599)
Net cash used in investing activities from continuing operations						(341,119)		(69,641)
Net cash used in investing activities from discontinued operations						0		0
Net cash used in investing activities						(341,119)		(69,641)

Cash flows from financing activities:
	Net change in bank borrowings					(5,381)		479,702
	Proceeds from issuance of long-term debt					200,000		501,421
	Principal payments for long-term debt					(120,326)		(609,580)
	Debt issuance costs					(199)		(3,655)
	Payments for repurchases of common stock					(201,211)		(73,789)
	Payments for taxes related to shares withheld for employee taxes					(7,359)		(13,713)
	Distributions to noncontrolling shareholders					(3,789)		(3,466)
	Acquisitions of noncontrolling interests in subsidiaries					(1,130)		(14,934)
	Proceeds from Henry Schein Animal Health Business					0		64
Net cash provided by (used in) financing activities from continuing operations						(139,395)		262,050
Net cash used in financing activities from discontinued operations						0		(573)
Net cash provided by (used in) financing activities						(139,395)		261,477
Effect of exchange rate changes on cash and cash equivalents from continuing operations						4,831		10,447
Effect of exchange rate changes on cash and cash equivalents from discontinued operations						0		0
Net change in cash and cash equivalents from continuing operations						(253,957)		190,013
Net change in cash and cash equivalents from discontinued operations						0		0
Cash and cash equivalents, beginning of period						421,185		106,097
Cash and cash equivalents, end of period					$	167,228	$	296,110

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1 – Basis of Presentation

Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period presentation.

Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements.

We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements.

For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At ~~September~~June 26, 2021 and December 26, 2020, ~~and December 28, 2019,~~there were 0 trade accounts receivable that ~~can only be used~~were restricted to settle obligations of this VIE, 0r were ~~$0 million and $127 million, respectively, and the~~there liabilities of the VIE where the creditors have recourse to ~~us were $0 million and $100 million, respectively.~~us.

The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December ~~28, 2019.~~

On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). All financial information within this Form 10-Q presents the Henry Schein Animal Health Business as a discontinued operation.26, 2020.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December ~~26, 2020.~~25, 2021.

In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic ~~has~~ negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. Demand increased in the ~~third quarter~~second half of 2020 and has continued into the first half of 2021, resulting in growth over the prior year driven by sales of personal protective equipment (PPE) and COVID-19 related products.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and ~~indefinite-lived~~definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a material adverse effect on our business, results of operations and cash flows, primarily in the second quarter of 2020. In the latter half of the second quarter of 2020, dental and medical practices began to re-open worldwide, and continued to do so during the ~~third quarter. However,~~second half of 2020. During the first half of 2021, patient ~~volumes remain below pre-COVID-19~~traffic levels ~~and certain regions in the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there~~returned to levels approaching pre-pandemic levels. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Note 2 – Discontinued Operations~~

~~Animal Health Spin-off~~

On the Distribution Date, we completed the Separation and subsequent Merger of the Henry Schein Animal Health Business with Vets First Choice. This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale Investors”) for $361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted basis, (i) approximately 63% of the shares of Covetrus common stock were (a) owned by our stockholders and the Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form of certain equity awards), and (ii) approximately 37% of the shares of Covetrus common stock were (a) owned by stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger, Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market.

In connection with the completion of the Animal Health Spin-off, we entered into a transition services agreement with Covetrus under which we have agreed to provide certain transition services for up to ~~twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services.~~

As a result of the Separation, the financial position and results of operations of the Henry Schein Animal Health Business are presented as discontinued operations and have been excluded from continuing operations and segment results for all periods presented. The accompanying Notes to the Consolidated Financial Statements have been revised to reflect the effect of the Separation and all prior year balances have been revised accordingly to reflect continuing operations only. The historical statements of Comprehensive Income (Loss) and Shareholders' Equity have not been revised to reflect the Separation and instead reflect the Separation as an adjustment to the balances at ~~September 28, 2019.~~

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Summarized financial information for our discontinued operations is as follows:~~

Three Months Ended

Nine Months Ended

September 26,

September 28,

September 26,

September 28,

2020

2019

2020

2019

Net sales

$
0

$
0

$
0

$
319,522
Cost of goods sold

0

0

0

260,097
Gross profit

0

0

0

59,425
Selling, general and administrative

326

1,063

782

68,013
Operating loss

(326)

(1,063)

(782)

(8,588)
Income tax benefit

(297)

(6,704)

(1,056)

(2,023)
Income (loss) from discontinued operations

(29)

5,641

274

(5,576)
Net loss attributable to noncontrolling interests

0

0

0

366
Net income (loss) from discontinued operations

attributable to Henry Schein, Inc.

(29)

5,641

274

(5,210)

~~The operating loss from discontinued operations for the three and nine months ended September 26, 2020 was primarily attributable to costs directly related to the Animal Health Spin-off. See~~ ~~Note 19-Related Party Transactions~~

~~for additional information.~~

The net income from discontinued operations for the nine months ended September 26, 2020 was primarily attributable to a tax refund received during Q2 2020 by a holding company previously part of our Animal Health legal structure.

The September 28, 2019 financial information above represents activity of the discontinued operations during the quarter and year-to-date through the Distribution Date. The income from discontinued operations for the three months ended September 28, 2019 was primarily attributable to a change in estimate of the tax deductibility of transaction costs incurred that were directly related to the Animal Health Spin-off. The loss from discontinued operations for the nine months ended September 28, 2019 was primarily attributable to the inclusion of the transaction costs directly related to the Animal Health Spin-off.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~The following are the amounts of assets and liabilities that were transferred to Covetrus as of February 7, 2019 and December 29, 2018.~~

February 7,

December 29,

2019

2018

Cash and cash equivalents

$
6,815

$
23,324
Accounts receivable, net

432,812

434,935
Inventories, net

536,637

555,230
Prepaid expenses and other

120,546

69,525

Total current assets of discontinued operations

1,096,810

1,083,014
Property and equipment, net

69,790

68,177
Operating lease right-of-use asset, net

57,012

0
Goodwill

742,931

739,266
Other intangibles, net

205,793

208,213
Investments and other

120,518

118,003

Total long-term assets of discontinued operations

1,196,044

1,133,659
Total assets of discontinued operations

$
2,292,854

$
2,216,673

Accounts payable

$
316,162

$
441,453
Current maturities of long-term debt

657

675
Operating lease liabilities

18,951

0
Accrued expenses:

Payroll and related

36,847

36,888

Taxes

24,060

17,552

Other

80,400

81,039

Total current liabilities of discontinued operations

477,077

577,607
Long-term debt

1,176,105

23,529
Deferred income taxes

17,019

4,352
Operating lease liabilities

38,668

0
Other liabilities

29,209

34,572

Total long-term liabilities of discontinued operations

1,261,001

62,453
Total liabilities of discontinued operations

$
1,738,078

$
640,060
Redeemable noncontrolling interests

$
28,270

$
92,432

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Note 32 – Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards

Critical Accounting Policies

There have been no material changes in our critical accounting policies during the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, as compared to the critical accounting policies described in Item 8 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December ~~28, 2019,~~26, 2020, except as follows:

Accounting Pronouncements Adopted

In ~~January 2017,~~December 2019, the Financial Accounting Standards Board ~~(the “FASB”~~(“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, “Intangibles-Goodwill and Other” (Topic 350) (“ASU 2017-04”). ASU 2017-04 eliminates step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. ASU 2017-04 requires us to perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. Our adoption of ASU 2017-04 on December 29, 2019 did not have a material impact on our consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. We adopted ASU 2016-13 using the modified-retrospective method and recorded an immaterial cumulative-effect adjustment to the opening balance of retained earnings. Based upon the level and makeup of our financial asset portfolio, including accounts receivable, past loan loss activity and current known activity regarding our outstanding loans, the adoption of ASU 2016-13 on December 29, 2019 resulted in a decrease of $0.4 million to retained earnings.

~~Recently Issued Accounting Standards~~

~~In December 2019, the FASB issued ASU~~ No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Our adoption of ASU ~~2017-04 is effective for fiscal years beginning after December 15, 2020. We do~~2019-12 did not ~~expect that the requirements of this ASU will~~ have a material impact on our consolidated financial statements.

Recently Issued Accounting Standards

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic 470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements.

1410

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 43 – Revenue from Contracts with Customers

Revenue is recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December ~~28, 2019.~~26, 2020.

Disaggregation of Revenue

The following table disaggregates our revenue by segment and geography:

			Three Months Ended						Nine Months Ended								Three Months Ended						Six Months Ended
			September 26, 2020						September 26, 2020								June 26, 2021						June 26, 2021
			North America		International		Global		North America		International		Global				North America		International		Global		North America		International		Global
Revenues:	Revenues:														Revenues:
Health care distribution	Health care distribution														Health care distribution
	Dental		$	1,008,836	$	641,017	$	1,649,853	$	2,413,154	$	1,653,067	$	4,066,221	Dental		$	1,127,607	$	782,737	$	1,910,344	$	2,172,390	$	1,526,882	$	3,699,272
	Medical			1,002,741		24,405		1,027,146		2,377,357		68,287		2,445,644	Medical			877,773		27,055		904,828		1,842,900		54,965		1,897,865
		Total health care distribution		2,011,577		665,422		2,676,999		4,790,511		1,721,354		6,511,865		Total health care distribution		2,005,380		809,792		2,815,172		4,015,290		1,581,847		5,597,137
Technology and value-added services	Technology and value-added services			120,949		17,406		138,355		327,374		48,173		375,547	Technology and value-added services			129,897		22,154		152,051		251,834		43,213		295,047
Total excluding Corporate TSA revenues ⁽¹⁾				2,132,526		682,828		2,815,354		5,117,885		1,769,527		6,887,412
Corporate TSA revenues ⁽¹⁾				0		24,792		24,792		0		66,004		66,004
		Total revenues	$	2,132,526	$	707,620	$	2,840,146	$	5,117,885	$	1,835,531	$	6,953,416		Total revenues	$	2,135,277	$	831,946	$	2,967,223	$	4,267,124	$	1,625,060	$	5,892,184

			Three Months Ended						Nine Months Ended								Three Months Ended						Six Months Ended
			September 28, 2019						September 28, 2019								June 27, 2020						June 27, 2020
			North America		International		Global		North America		International		Global				North America		International		Global		North America		International		Global
Revenues:	Revenues:														Revenues:
Health care distribution	Health care distribution														Health care distribution
	Dental		$	951,792	$	594,189	$	1,545,981	$	2,850,669	$	1,843,042	$	4,693,711	Dental		$	515,946	$	425,346	$	941,292	$	1,404,318	$	1,012,050	$	2,416,368
	Medical			784,349		19,360		803,709		2,125,002		59,925		2,184,927	Medical			596,588		21,222		617,810		1,374,616		43,882		1,418,498
		Total health care distribution		1,736,141		613,549		2,349,690		4,975,671		1,902,967		6,878,638		Total health care distribution		1,112,534		446,568		1,559,102		2,778,934		1,055,932		3,834,866
Technology and value-added services	Technology and value-added services			120,199		17,135		137,334		327,709		50,274		377,983	Technology and value-added services			92,927		12,300		105,227		206,425		30,767		237,192
Total excluding Corporate TSA revenues ⁽¹⁾	Total excluding Corporate TSA revenues ⁽¹⁾			1,856,340		630,684		2,487,024		5,303,380		1,953,241		7,256,621	Total excluding Corporate TSA revenues ⁽¹⁾			1,205,461		458,868		1,664,329		2,985,359		1,086,699		4,072,058
Corporate TSA revenues ⁽¹⁾	Corporate TSA revenues ⁽¹⁾			1,077		20,666		21,743		4,098		56,143		60,241	Corporate TSA revenues ⁽¹⁾			0		20,070		20,070		0		41,212		41,212
		Total revenues	$	1,857,417	$	651,350	$	2,508,767	$	5,307,478	$	2,009,384	$	7,316,862		Total revenues	$	1,205,461	$	478,938	$	1,684,399	$	2,985,359	$	1,127,911	$	4,113,270

(1)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered
	into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.

(1)Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. See Note-18 Related Party Transactions for further information.

At December ~~28, 2019,~~26, 2020, the current portion of contract liabilities of ~~$70.8~~$71.5 million was reported in Accrued expenses: Other, and ~~$6.2~~$8.2 million related to non-current contract liabilities ~~were~~was reported in Other liabilities. During the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, we recognized in revenue ~~$60.0~~$47.1 million of the amounts that were previously deferred at December ~~28, 2019.~~26, 2020. At ~~September~~June 26, ~~2020,~~2021, the current and non-current portion of contract liabilities were ~~$58.3~~$70.9 million and ~~$6.8~~$9.0 million, respectively.

1511

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 54 – Segment Data

We conduct our business through 2 reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base.

The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental and medical groups serve practitioners in 3132 countries worldwide.

Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners.

The following tables present information about our reportable and operating segments:

Three Months Ended

Nine Months Ended

September 26,

September 28,

September 26,

September 28,

2020

2019

2020

2019
Net Sales:

Health care distribution ⁽¹⁾

Dental

$
1,649,853

$
1,545,981

$
4,066,221

$
4,693,711

Medical

1,027,146

803,709

2,445,644

2,184,927

Total health care distribution

2,676,999

2,349,690

6,511,865

6,878,638

Technology and value-added services ⁽²⁾

138,355

137,334

375,547

377,983

Total excluding Corporate TSA revenue

2,815,354

2,487,024

6,887,412

7,256,621

Corporate TSA revenues ⁽³⁾

24,792

21,743

66,004

60,241

Total

$
2,840,146

$
2,508,767

$
6,953,416

$
7,316,862

(1)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)
Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)
Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.

Three Months Ended

Nine Months Ended

September 26,

September 28,

September 26,

September 28,

2020

2019

2020

2019
Operating Income:

Health care distribution

$
148,657

$
149,495

$
271,477

$
428,934

Technology and value-added services

39,014

37,703

82,626

92,993

Total

$
187,671

$
187,198

$
354,103

$
521,927

			Three Months Ended				Six Months Ended
			June 26,		June 27,		June 26,		June 27,
			2021		2020		2021		2020
Net Sales:
	Health care distribution ⁽¹⁾
		Dental	$	1,910,344	$	941,292	$	3,699,272	$	2,416,368
		Medical		904,828		617,810		1,897,865		1,418,498
		Total health care distribution		2,815,172		1,559,102		5,597,137		3,834,866
	Technology and value-added services ⁽²⁾			152,051		105,227		295,047		237,192
		Total excluding Corporate TSA revenue		2,967,223		1,664,329		5,892,184		4,072,058
	Corporate TSA revenues ⁽³⁾			0		20,070		0		41,212
		Total	$	2,967,223	$	1,684,399	$	5,892,184	$	4,113,270

(1)Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins.

(2)Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. See Note-18 Related Party Transactions for further information.

			Three Months Ended				Six Months Ended
			June 26,		June 27,		June 26,		June 27,
			2021		2020		2021		2020
Operating Income (Loss):
	Health care distribution		$	181,761	$	(25,348)	$	379,693	$	122,819
	Technology and value-added services			28,585		17,915		60,581		43,613
		Total	$	210,346	$	(7,433)	$	440,274	$	166,432

1612

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 65 – Debt

Bank Credit Lines

Bank credit lines consisted of the following:

		September 26,		December 28,			June 26,		December 26,
		2020		2019			2021		2020
Revolving credit agreement	Revolving credit agreement	$	0	$	0	Revolving credit agreement	$	0	$	0
364-day credit agreement			500,000		0
Other short-term bank credit lines	Other short-term bank credit lines		7,372		23,975	Other short-term bank credit lines		72,105		73,366
Total	Total	$	507,372	$	23,975	Total	$	72,105	$	73,366

~~The increase in the level of borrowings under our bank credit lines as of September 26, 2020 was attributable to potential cash requirements due to the impact of the COVID-19 pandemic.~~

Revolving Credit Agreement

On April 18, 2017, we entered into a $750 million revolving credit agreement (the “Credit Agreement”), which matures in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. We expect ~~the~~most LIBOR ~~rate~~rates to be discontinued ~~at some point during~~immediately after December 31, 2021, while the remaining LIBOR rates will be discontinued immediately after June 30, 2023, which will require an amendment to our debt agreements to reflect a new reference rate. We do not expect the discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our financial position or to materially affect our interest expense. The Credit Agreement also requires, among other things, that we maintain maximum leverage ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of ~~September~~June 26, 2021, and December 26, 2020, ~~and December 28, 2019, the~~we had no borrowings onunder this revolving credit ~~facility~~facility. As of June 26, 2021, and December 26, 2020, there were $~~0.0~~9.3 million and ~~$0.0 million, respectively. As of September 26, 2020 and December 28, 2019, there were~~ $9.5 ~~million and $9.6~~ million of letters of credit, respectively, provided to third parties under the credit facility.

On April 17, 2020, we amended the Credit Agreement to, among other things, (i) modify the financial covenant from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021.

364-Day Credit Agreement

On ~~April 17, 2020,~~March 4, 2021, we ~~entered into a new~~repaid the outstanding obligations and terminated the lender commitments under our $700 million 364-day credit agreement ~~with JPMorgan Chase Bank, N.A. and U.S. Bank National Association as joint lead arrangers and joint bookrunners.~~which was entered into on April 17, 2020. This facility ~~matures~~was originally scheduled to mature on April 16, 2021. As of September 26, 2020, the borrowings on this credit facility were $500 million. We have the ability to borrow the remaining $200 million on a revolving basis as needed, subject to the terms and conditions of the credit agreement. ~~The interest rate for borrowings under this facility will fluctuate based on our net leverage ratio. At September 26, 2020, the interest rate on this facility was~~ ~~2.81%. The proceeds from this facility can be used for working capital requirements and general corporate purposes, including, but not limited to, permitted refinancing of existing indebtedness.~~

Other Short-Term Credit Lines

As of June 26, 2021 and December 26, 2020, we had various other short-term bank credit lines available, of which $72.1 million and $73.4 million, respectively, were outstanding. At June 26, 2021 and December 26, 2020, borrowings under all of these credit lines had a weighted average interest rate of 5.98% and 4.14%, respectively.

1713

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

~~Other Short-Term Credit Lines~~

As of September 26, 2020 and December 28, 2019, we had various other short-term bank credit lines available, of which $7.4 million and $24 million, respectively, were outstanding. At September 26, 2020 and December 28, 2019, borrowings under all of these credit lines had a weighted average interest rate of 2.82% and 3.45%, respectively.

The decrease during the quarter ended September 26, 2020 in the weighted average interest rate under all of our credit lines was attributable to the Federal Reserve lowering borrowing rates during March 2020 in response to the COVID-19 pandemic.

Long-term debt

Long-term debt consisted of the following:

		September 26,		December 28,			June 26,		December 26,
		2020		2019			2021		2020
Private placement facilities	Private placement facilities	$	613,549	$	621,274	Private placement facilities	$	706,332	$	613,498
U.S. trade accounts receivable securitization			0		100,000
Note payable due in 2025 with an interest rate of 3.1%
	at September 26, 2020		1,438		0
Note payable						Note payable		0		1,554
Various collateralized and uncollateralized loans payable with interest,	Various collateralized and uncollateralized loans payable with interest,					Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2023 at interest rates					in varying installments through 2023 at interest rates
	ranging from 2.62% to 4.22% at September 26, 2020 and					ranging from 2.45% to 4.27% at June 26, 2021 and
	ranging from 2.56% to 10.5% at December 28, 2019		4,273		6,089	ranging from 2.62% to 4.27% at December 26, 2020		4,293		4,596
Finance lease obligations (see Note 7)			6,112		5,394
Finance lease obligations (see Note 6)						Finance lease obligations (see Note 6)		5,701		5,961
	Total		625,372		732,757	Total		716,326		625,609
Less current maturities	Less current maturities		(110,015)		(109,849)	Less current maturities		(9,839)		(109,836)
	Total long-term debt	$	515,357	$	622,908	Total long-term debt	$	706,487	$	515,773

Private Placement Facilities

~~On September 15, 2017, we increased our available~~Our private placement facilities, with ~~three~~3 insurance companies, tohave a total facility amount of $1 ~~billion. On June 23, 2020, the expiration date for our private placement facilities was extended through June 23, 2023. These facilities~~billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through June 23, 2023. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. On June 29, 2018, we amended and restated the above private placement facilities to, among other things, (i) permit the consummation of the Animal Health Spin-off and (ii) provide for the issuance of notes in Euros, British Pounds and Australian Dollars, in addition to U.S. Dollars. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

On ~~June 23, 2020,~~March 5, 2021, we amended the private placement facilities to, among other things, ~~(i) temporarily~~(a) modify the financial covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum maintenance total leverage ratio to ~~net leverage ratio until March 31, 2021, (ii) increase~~3.25x and remove the ~~maximum maintenance leverage ratio through March 31, 2021, but with a~~ 1.00% interest rate increase ~~on the outstanding notes~~triggered if the net leverage ratio ~~exceeds 3.0x, which will remain in effect until we deliver financials for a~~were to exceed 3.0x.

1814

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

four-quarter period ending on or after June 30, 2021 showing compliance with the total leverage ratio requirement, and (iii) make certain other changes conforming to the Credit Agreement, dated as of April 18, 2017.

The components of our private placement facility borrowings as of ~~September~~June 26, ~~2020~~2021 are presented in the following table (in thousands):

Amount of

Borrowing

Borrowing

Date of Borrowing

Outstanding

Rate

Due Date
January 20, 2012 (1)

$
14,286

3.09
%

January 20, 2022
January 20, 2012

50,000

3.45

January 20, 2024
December 24, 2012

50,000

3.00

December 24, 2024
June 2, 2014

100,000

3.19

June 2, 2021
June 16, 2017

100,000

3.42

June 16, 2027
September 15, 2017

100,000

3.52

September 15, 2029
January 2, 2018

100,000

3.32

January 2, 2028
September 2, 2020 (2)

100,000

2.35

September 3, 2030
Less: Deferred debt issuance costs

(737)

$
613,549

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.
(2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030.


	Amount of
	Borrowing		Borrowing
Date of Borrowing	Outstanding		Rate		Due Date
January 20, 2012 (1)	$	7,143	3.09	%	January 20, 2022
January 20, 2012		50,000	3.45		January 20, 2024
December 24, 2012		50,000	3.00		December 24, 2024
June 16, 2017		100,000	3.42		June 16, 2027
September 15, 2017		100,000	3.52		September 15, 2029
January 2, 2018		100,000	3.32		January 2, 2028
September 2, 2020		100,000	2.35		September 2, 2030
June 2, 2021		100,000	2.48		June 2, 2031
June 2, 2021		100,000	2.58		June 2, 2033
Less: Deferred debt issuance costs		(811)
	$	706,332

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. Our current facility, which has a purchase limit of $350 million, was scheduled to expire on April 29, 2022. On June 22, 2020, the expiration date for this facility was extended to June 12, ~~2023.~~2023 and was amended to adjust certain covenant levels for 2020. As of ~~September~~June 26, 2021 and December 26, 2020, ~~and December 28, 2019, the~~there were 0 borrowings outstanding under this securitization facility. At June 26, 2021, the interest rate on borrowings under this facility ~~were $0 million and $100 million, respectively.~~was based on the asset-backed commercial paper rate of 0.14% plus 0.95%, for a combined rate of 1.09%. At ~~September~~December 26, 2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.22% plus 0.95%, for a combined rate of 1.17%~~. At December 28, 2019, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 1.90% plus 0.75%, for a combined rate of 2.65%~~.

If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of 25 to 45 basis points depending upon program utilization.

~~Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance sheets.~~

~~On June 22, 2020 we amended this facility to adjust certain covenant levels, in particular for the second and third quarters of 2020.~~

1915

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 76 – Leases

Leases

Three Months Ended

Nine Months Ended

September 26,

September 28,

September 26,

September 28,

2020

2019

2020

2019

Operating lease cost:^{(1) (2)}

$
21,343

$
21,840

$
65,413

$
68,273

Finance lease cost:

Amortization of right-of-use assets

434

290

1,148

798

Interest on lease liabilities

29

31

86

88

Total finance lease cost

$
463

$
321

$
1,234

$
886

(1)
Includes variable lease expenses.

(2)
Operating lease (credit) cost for three months and nine months ended September 26, 2020, includes amortization of right-of-use assets of $(0.1) and $ 0.40 million, respectively, related to facility leases recorded in “Restructuring costs” within our consolidated statements of income.

Supplemental balance sheet information related to leases is as follows:

September 26,

December 28,

2020

2019

Operating Leases:

Operating lease right-of-use assets

$
249,895

$
231,662

Current operating lease liabilities

62,914

65,349

Non-current operating lease liabilities

200,611

176,267

Total operating lease liabilities

$
263,525

$
241,616

Finance Leases:

Property and equipment, at cost

$
10,457

$
10,268

Accumulated depreciation

(4,030)

(4,581)

Property and equipment, net of accumulated depreciation

$
6,427

$
5,687

Current maturities of long-term debt

$
2,348

$
1,736

Long-term debt

3,764

3,658

Total finance lease liabilities

$
6,112

$
5,394

Weighted Average Remaining Lease Term in Years:

Operating leases

7.1

5.5

Finance leases

4.3

5.0

Weighted Average Discount Rate:

Operating leases

3.0
%

3.4
%

Finance leases

2.0
%

2.2
%

		Three Months Ended				Six Months Ended
		June 26,		June 27,		June 26,		June 27,
		2021		2020		2021		2020
Operating lease cost:⁽¹⁾		$	25,840	$	21,991	$	48,946	$	44,070
Finance lease cost:
Amortization of right-of-use assets			516		282		1,120		714
Interest on lease liabilities			27		20		53		57
Total finance lease cost		$	543	$	302	$	1,173	$	771

(1)	Includes variable lease expenses.


Supplemental balance sheet information related to leases is as follows:

		June 26,			December 26,
		2021			2020
Operating Leases:
Operating lease right-of-use assets		$	301,440		$	288,847

Current operating lease liabilities			75,008			64,716
Non-current operating lease liabilities			243,232			238,727
	Total operating lease liabilities	$	318,240		$	303,443

Finance Leases:
Property and equipment, at cost		$	11,443		$	10,683
Accumulated depreciation			(5,170)			(4,277)
Property and equipment, net of accumulated depreciation		$	6,273		$	6,406

Current maturities of long-term debt		$	2,420		$	2,420
Long-term debt			3,281			3,541
	Total finance lease liabilities	$	5,701		$	5,961

Weighted Average Remaining Lease Term in Years:
	Operating leases		7.1			7.5
	Finance leases		4.0			4.3

Weighted Average Discount Rate:
	Operating leases		2.6	%		2.8	%
	Finance leases		1.8	%		1.9	%

2016

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Supplemental cash flow information related to leases is as follows:	Supplemental cash flow information related to leases is as follows:					Supplemental cash flow information related to leases is as follows:

			Nine Months Ended					Six Months Ended
		September 26,		September 28,			June 26,		June 27,
		2020		2019			2021		2020
Cash paid for amounts included in the measurement of lease liabilities:	Cash paid for amounts included in the measurement of lease liabilities:					Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows for operating leases	$	57,666	$	60,275	Operating cash flows for operating leases	$	39,988	$	38,579
	Operating cash flows for finance leases		76		67	Operating cash flows for finance leases		47		50
	Financing cash flows for finance leases		1,515		862	Financing cash flows for finance leases		1,407		947
Right-of-use assets obtained in exchange for lease obligations:	Right-of-use assets obtained in exchange for lease obligations:					Right-of-use assets obtained in exchange for lease obligations:
	Operating leases	$	66,082	$	290,166	Operating leases	$	49,226	$	14,926
	Finance leases		2,489		1,149	Finance leases		1,244		1,814

Maturities of lease liabilities are as follows:	Maturities of lease liabilities are as follows:					Maturities of lease liabilities are as follows:

			September 26, 2020					June 26, 2021
			Operating		Finance			Operating		Finance
			Leases		Leases			Leases		Leases
2020		$	18,423	$	747
2021	2021		65,955		2,272	2021	$	42,284	$	1,384
2022	2022		49,257		1,365	2022		72,260		1,930
2023	2023		32,363		495	2023		49,569		963
2024	2024		22,298		315	2024		35,148		393
2025						2025		30,519		337
Thereafter	Thereafter		103,765		1,163	Thereafter		118,761		895
Total future lease payments	Total future lease payments		292,061		6,357	Total future lease payments		348,541		5,902
Less imputed interest			(28,536)		(245)
Less: imputed interest						Less: imputed interest		(30,301)		(201)
Total	Total	$	263,525	$	6,112	Total	$	318,240	$	5,701

As of ~~September~~June 26, ~~2020,~~2021, we have additional operating leases with total lease payments of ~~$12.7~~$12.5 million for buildings and vehicles that have not yet commenced. These operating leases will commence subsequent to ~~September~~June 26, ~~2020,~~2021, with lease terms of ~~13 months~~two years to 10 years.

2117

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 87 – Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and the year ended December ~~28, 2019~~26, 2020 are presented in the following table:

September 26,

December 28,

2020

2019
Balance, beginning of period

$
287,258

$
219,724
Decrease in redeemable noncontrolling interests due to

redemptions

(12,636)

(2,270)
Increase in redeemable noncontrolling interests due to business

acquisitions

25,955

74,865
Net income attributable to redeemable noncontrolling interests

7,253

14,838
Dividends declared

(7,272)

(10,264)
Effect of foreign currency translation loss attributable to

redeemable noncontrolling interests

(10,999)

(2,335)
Change in fair value of redeemable securities

5,141

(7,300)
Balance, end of period

$
294,700

$
287,258

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

		June 26,		December 26,
		2021		2020
Balance, beginning of period		$	327,699	$	287,258
Decrease in redeemable noncontrolling interests due to
	redemptions		(1,130)		(17,241)
Increase in redeemable noncontrolling interests due to business
	acquisitions		140,155		28,387
Net income attributable to redeemable noncontrolling interests			14,033		13,363
Dividends declared			(9,954)		(12,631)
Effect of foreign currency translation gain (loss) attributable to
	redeemable noncontrolling interests		570		(4,279)
Change in fair value of redeemable securities			132,708		32,842
Balance, end of period		$	604,081	$	327,699

Note 98 – Comprehensive Income

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity.

The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of:

September 26,

December 28,

2020

2019
Attributable to Redeemable noncontrolling interests:

Foreign currency translation adjustment

$
(31,337)

$
(20,338)

Attributable to noncontrolling interests:

Foreign currency translation adjustment

$
(276)

$
(531)

Attributable to Henry Schein, Inc.:

Foreign currency translation adjustment

$
(149,744)

$
(143,172)

Unrealized loss from foreign currency hedging activities

(1,575)

(4,032)

Unrealized investment gain

1

6

Pension adjustment loss

(20,014)

(20,175)

Accumulated other comprehensive loss

$
(171,332)

$
(167,373)

Total Accumulated other comprehensive loss

$
(202,945)

$
(188,242)

~~The following table summarizes the components of comprehensive income, net of applicable taxes as follows:~~

Three Months Ended

Nine Months Ended

September 26,

September 28,

September 26,

September 28,

2020

2019

2020

2019
Net income

$
151,784

$
148,853

$
272,082

$
382,693

Foreign currency translation gain (loss)

37,588

(60,635)

(17,316)

(43,926)
Tax effect

0

0

0

0
Foreign currency translation gain (loss)

37,588

(60,635)

(17,316)

(43,926)

Unrealized gain (loss) from foreign currency hedging

activities

(10,490)

(1,685)

3,010

(2,037)
Tax effect

2,793

422

(553)

451
Unrealized gain (loss) from foreign currency hedging

activities

(7,697)

(1,263)

2,457

(1,586)

Unrealized investment gain (loss)

2

3

(6)

10
Tax effect

0

(1)

1

(2)
Unrealized investment gain (loss)

2

2

(5)

8

Pension adjustment gain (loss)

(471)

585

227

1,146
Tax effect

133

(185)

(66)

(314)
Pension adjustment gain (loss)

(338)

400

161

832
Comprehensive income

$
181,339

$
87,357

$
257,379

$
338,021

			June 26,		December 26,
			2021		2020
Attributable to Redeemable noncontrolling interests:
		Foreign currency translation adjustment	$	(24,047)	$	(24,617)

Attributable to noncontrolling interests:
		Foreign currency translation adjustment	$	466	$	235

Attributable to Henry Schein, Inc.:
	Foreign currency translation adjustment		$	(77,709)	$	(76,565)
	Unrealized loss from foreign currency hedging activities			(9,878)		(11,488)
	Unrealized investment gain (loss)			(2)		1
	Pension adjustment loss			(19,190)		(20,032)
		Accumulated other comprehensive loss	$	(106,779)	$	(108,084)

Total Accumulated other comprehensive loss			$	(130,360)	$	(132,466)

2318

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The following table summarizes the components of comprehensive income, net of applicable taxes as follows:

	Three Months Ended				Six Months Ended
	June 26,		June 27,		June 26,		June 27,
	2021		2020		2021		2020
Net income (loss)	$	163,977	$	(13,267)	$	338,905	$	120,298

Foreign currency translation gain (loss)		38,138		34,408		(343)		(54,904)
Tax effect		0		0		0		0
Foreign currency translation gain (loss)		38,138		34,408		(343)		(54,904)

Unrealized gain (loss) from foreign currency hedging
activities		(2,438)		(6,733)		2,257		13,500
Tax effect		687		1,744		(647)		(3,346)
Unrealized gain (loss) from foreign currency hedging
activities		(1,751)		(4,989)		1,610		10,154

Unrealized investment gain (loss)		4		3		(4)		(8)
Tax effect		(1)		(1)		1		1
Unrealized investment gain (loss)		3		2		(3)		(7)

Pension adjustment gain (loss)		(3)		(350)		1,023		698
Tax effect		38		125		(181)		(199)
Pension adjustment gain (loss)		35		(225)		842		499
Comprehensive income	$	200,402	$	15,929	$	341,011	$	76,040

The change in the unrealized gain (loss) from foreign currency hedging activities during the three months and year ended ~~September~~June 26, ~~2020,~~2021, compared to the comparable prior year period, was primarily attributable to a net investment hedge that was entered into during 2019. See Note ~~15-Derivatives~~14-Derivatives and Hedging Activities

for further information.

Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~nine~~six months ended ~~September 28, 2019~~June 27, 2020 was primarily impacted by changes in foreign currency exchange rates of the Euro, British Pound, Brazilian Real, Australian Dollar and Canadian Dollar.

The following table summarizes our total comprehensive income, net of applicable taxes, as follows:

		Three Months Ended				Nine Months Ended					Three Months Ended				Six Months Ended
		September 26,		September 28,		September 26,		September 28,			June 26,		June 27,		June 26,		June 27,
		2020		2019		2020		2019			2021		2020		2021		2020
Comprehensive income attributable to	Comprehensive income attributable to									Comprehensive income attributable to
	Henry Schein, Inc.	$	169,616	$	85,075	$	257,202	$	324,809	Henry Schein, Inc.	$	185,242	$	17,600	$	323,018	$	87,586
Comprehensive income attributable to
Comprehensive income (loss) attributable to										Comprehensive income (loss) attributable to
	noncontrolling interests		4,354		3,924		3,923		7,280	noncontrolling interests		1,437		(744)		3,390		(431)
Comprehensive income (loss) attributable to	Comprehensive income (loss) attributable to									Comprehensive income (loss) attributable to
	Redeemable noncontrolling interests		7,369		(1,642)		(3,746)		5,932	Redeemable noncontrolling interests		13,723		(927)		14,603		(11,115)
Comprehensive income	Comprehensive income	$	181,339	$	87,357	$	257,379	$	338,021	Comprehensive income	$	200,402	$	15,929	$	341,011	$	76,040

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 109 – Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ~~The~~Fair value hierarchy ~~for determining that~~ distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows:

• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

• Level 3— Inputs that are unobservable for the asset or liability.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values.

Investments and notes receivable

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets.

Debt

The fair value of our debt (including bank credit lines) is classified as Level 3 within the fair value hierarchy as of ~~September~~June 26, ~~2020~~2021 and December ~~28, 2019~~26, 2020 was estimated at ~~$1,132.7~~$788.4 million and ~~$756.7~~$699.0 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads.

Derivative contracts

Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan and our deferred compensation plan.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. See Note ~~15-Derivatives~~14-Derivatives and Hedging Activities

for further information.

Redeemable noncontrolling interests

The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. See Note 8–7–Redeemable Noncontrolling Interests

for additional information.

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 26, 2021 and December 26, 2020:

			June 26, 2021
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	0	$	1,471	$	0	$	1,471
	Total return swaps			0		1,317		0		1,317
		Total assets	$	0	$	2,788	$	0	$	2,788

Liabilities:
	Derivative contracts		$	0	$	9,542	$	0	$	9,542
		Total liabilities	$	0	$	9,542	$	0	$	9,542

Redeemable noncontrolling interests			$	0	$	0	$	604,081	$	604,081

			December 26, 2020
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	0	$	1,868	$	0	$	1,868
	Total return swaps			0		1,565		0		1,565
		Total assets	$	0	$	3,433	$	0	$	3,433

Liabilities:
	Derivative contracts		$	0	$	11,765	$	0	$	11,765
		Total liabilities	$	0	$	11,765	$	0	$	11,765

Redeemable noncontrolling interests			$	0	$	0	$	327,699	$	327,699

2521

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

September 26, 2020

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts

$
0

$
32,107

$
0

$
32,107

Total assets

$
0

$
32,107

$
0

$
32,107

Liabilities:

Derivative contracts

$
0

$
4,175

$
0

$
4,175

Total return swaps

0

2,406

0

2,406

Total liabilities

$
0

$
6,581

$
0

$
6,581

Redeemable noncontrolling interests

$
0

$
0

$
294,700

$
294,700

December 28, 2019

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts

$
0

$
567

$
0

$
567

Total assets

$
0

$
567

$
0

$
567

Liabilities:

Derivative contracts

$
0

$
5,795

$
0

$
5,795

Total liabilities

$
0

$
5,795

$
0

$
5,795

Redeemable noncontrolling interests

$
0

$
0

$
287,258

$
287,258

Note 1110 – Business Acquisitions

Acquisitions

~~The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates.~~

We completed acquisitions during the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 which were immaterial to our financial ~~statements individually. In~~statements. The acquisitions that we completed included companies within our Health care distribution and Technology and value-added services segments. The initial ownership interest we acquired in these companies ranged from approximately 51% to 100%. Acquisitions within our Health care distribution segment included companies that specialize in the ~~aggregate, these transactions resulted in~~distribution of dental products, a provider of home medical supplies, and a provider of product kitting and sterile packaging. Within our Technology and value-added services segment, we acquired companies that focus on dental marketing and website solutions, practice transition services, and business analytics and intelligence software.

The following table summarizes the estimated fair value, as of the date of acquisition, of consideration ~~of $47.1 million~~paid and net assets acquired for acquisitions during the ~~nine~~six months ended ~~September~~June 26, ~~2020 related~~2021. While we use our best estimates and assumptions to ~~business combinations, for net~~accurately value those assets ~~amounting~~acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to ~~$16.9 million.~~refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets.

Acquisition consideration:
Cash	$	310,523
Redeemable noncontrolling interests		129,319
Total consideration		439,842

Identifiable assets acquired and liabilities assumed:
Current assets		107,197
Intangible assets		183,796
Other noncurrent assets		33,959
Current liabilities		(43,781)
Deferred income taxes		(17,442)
Other noncurrent liabilities		(37,462)
Total identifiable net assets		226,267
Goodwill		213,575
Total net assets acquired	$	439,842

The major classes of ~~September 26, 2020,~~assets and liabilities that we ~~had recorded $29.1 million~~generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete agreements and product development), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable ~~intangibles, $34.7 million~~intangible assets is based on critical estimates, judgments and assumptions derived from analysis of ~~goodwill~~market conditions, discount rates, discounted cash flows, customer retention rates and ~~$24.2 million of non-controlling interest, related to these acquisitions.~~estimated useful lives.

Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019,~~June 27, 2020, there were no material adjustments recorded in our consolidated statements of income relating to changes in estimated contingent purchase price liabilities.

2622

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1211 – Plans of Restructuring

On July 9, 2018, we committed to an initiative to rationalize our operations and provide expense efficiencies. These actions allowed us to execute on our plan to reduce our cost structure and fund new initiatives that drive growth under our 2018 to 2020 strategic plan. This initiative has resulted in the elimination of approximately 4% of our workforce and the closing of certain facilities.

On November 20, 2019, we committed to a contemplated initiative, intended to mitigate stranded costs associated with the Animal Health Spin-off and to rationalize operations and to provide expense efficiencies. These activities were originally expected to be completed by the end of 2020. ~~We are re-assessing that timeline in~~In light of the ~~current~~changes to the business environment brought on by the COVID-19 ~~pandemic.~~pandemic, we extended such activities to the end of 2021.

During the three months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019, we recorded restructuring costs (credits) of $7.0 million and $(0.8) million. During the nine months ended September 26,~~June 27, 2020, ~~and September 28, 2019,~~ we recorded restructuring costs of ~~$27.7~~$0.6 million and ~~$15.8~~$15.9 million. During the six months ended June 26, 2021 and June 27, 2020, we recorded restructuring costs of $3.5 million and $20.7 million. The restructuring costs for these periods included costs for severance benefits and facility exit costs. The costs associated with these restructurings are included in a separate line item, “Restructuring costs” within our consolidated statements of income.

We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities in 2021, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures.

The following table shows the net amounts expensed and paid for restructuring costs that were incurred during the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and during our ~~2019~~2020 fiscal year and the remaining accrued balance of restructuring costs as of ~~September~~June 26, ~~2020,~~2021, which is included in Accrued expenses: Other within our consolidated balance sheets:

				Facility									Facility
		Severance		Closing							Severance		Closing
		Costs		Costs		Other		Total			Costs		Costs		Other		Total
Balance, December 29, 2018		$	29,964	$	1,603	$	158	$	31,725
Provision			13,741		937		27		14,705
Payments and other adjustments			(30,794)		(1,714)		(112)		(32,620)
Balance, December 28, 2019	Balance, December 28, 2019	$	12,911	$	826	$	73	$	13,810	Balance, December 28, 2019	$	12,911	$	826	$	73	$	13,810
Provision	Provision		23,127		4,348		238		27,713	Provision		25,855		5,878		360		32,093
Payments and other adjustments	Payments and other adjustments		(21,404)		(4,609)		(247)		(26,260)	Payments and other adjustments		(26,152)		(6,309)		(329)		(32,790)
Balance, September 26, 2020		$	14,634	$	565	$	64	$	15,263
Balance, December 26, 2020										Balance, December 26, 2020	$	12,614	$	395	$	104	$	13,113
Provision										Provision		3,436		(122)		221		3,535
Payments and other adjustments										Payments and other adjustments		(12,736)		50		(321)		(13,007)
Balance, June 26, 2021										Balance, June 26, 2021	$	3,314	$	323	$	4	$	3,641

The following table shows, by reportable segment, the net amounts expensed and paid for restructuring costs that were incurred during the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and during our ~~2019~~2020 fiscal year and the remaining accrued balance of restructuring costs as of ~~September~~June 26, ~~2020:~~2021:

Technology and

Health Care

Value-Added

Distribution

Services

Total
Balance, December 29, 2018

$
30,291

$
1,434

$
31,725
Provision

13,935

770

14,705
Payments and other adjustments

(30,853)

(1,767)

(32,620)
Balance, December 28, 2019

$
13,373

$
437

$
13,810
Provision

26,621

1,092

27,713
Payments and other adjustments

(25,175)

(1,085)

(26,260)
Balance, September 26, 2020

$
14,819

$
444

$
15,263

			Technology and
	Health Care		Value-Added
	Distribution		Services		Total
Balance, December 28, 2019	$	13,373	$	437	$	13,810
Provision		30,935		1,158		32,093
Payments and other adjustments		(31,484)		(1,306)		(32,790)
Balance, December 26, 2020	$	12,824	$	289	$	13,113
Provision		3,082		453		3,535
Payments and other adjustments		(12,561)		(446)		(13,007)
Balance, June 26, 2021	$	3,345	$	296	$	3,641

2723

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1312 – Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

Three Months Ended

Nine Months Ended

September 26,

September 28,

September 26,

September 28,

2020

2019

2020

2019
Basic

142,362

147,136

142,553

148,603
Effect of dilutive securities:

Restricted stock and restricted stock units

729

1,439

755

1,317

Diluted

143,091

148,575

143,308

149,920

		Three Months Ended		Six Months Ended
		June 26,	June 27,	June 26,	June 27,
		2021	2020	2021	2020
Basic		140,358	142,350	141,316	142,654
Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,299	0	1,222	0
	Diluted	141,657	142,350	142,538	142,654

2824

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1413 – Income Taxes

For the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021 our effective tax rate was ~~20.0%~~24.3% compared to ~~23.9%~~24.2% for the prior year period. The difference between our effective tax ~~rate~~rates and the federal statutory tax rate for the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~ 2021~~was~~ primarily ~~due~~relates to ~~a U.S. federal income tax settlement reached during the third quarter, which lowered income tax expense by approximately $15.6 million, as well as~~ state and foreign income taxes, interest expense and ~~interest.~~tax charges and credits associated with legal entity reorganizations. The difference between our effective tax rate and the federal statutory tax rate for the ~~nine~~six months ended ~~September 28, 2019~~June 27, 2020 primarily relates to state and foreign income taxes and interest ~~expense.~~expense, tax charges and credits associated with legal entity reorganizations outside the U.S and a valuation allowance recognized on a portion of a deferred tax asset.

The American Rescue Plan Act of 2021 (“ARPA”) was signed into law on March 11, 2021. The ARPA included a corporate income tax provision to further limit the deductibility of compensation under Section 162(m) for tax years starting after December 31, 2026. Section 162(m) generally limits the deductibility of compensation paid to covered employees of publicly held corporations. Covered employees include the CEO, CFO and the three highest paid officers. The ARPA expands the group of covered employees to additionally include five of the highest paid employees.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act includes, but is not limited to, certain income tax provisions that modify the Section 163(j) limitation of business interest and ~~Net Operating Loss (“NOL”)~~net operating loss carryover and carryback rules. The modifications to Section 163(j) increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income for years beginning in 2019 and 2020. The CARES Act eliminated the NOL income limitation for years beginning before 2021 and it extended the carryback period to five years for year losses incurred in 2018, 2019 and 2020. We have analyzed the income tax provisions of the CARES Act and have accounted for the impact in the ~~nine~~six months ended ~~September 26,~~June 27, 2020, which did not have a material impact on our consolidated financial statements. There are certain other non-income tax benefits available to us under the CARES Act that require further clarification or interpretation that may affect our consolidated financial statements in the future.

On July 20, 2020, the U.S Internal Revenue Service (the “IRS”) issued final regulations related to the 2017 Tax Cuts and Jobs Act (“Tax Act”). The final regulations concern the global intangible low-taxed income (“GILTI”) and subpart F income provisions of the Tax Act. To provide flexibility to taxpayers, the IRS is permitting the application of these final regulations to prior tax years, if the taxpayer elects to do so. We have analyzed the final regulations, which do not have a material impact to our consolidated financial statements.

The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated balance sheets, as of ~~September~~June 26, ~~2020~~2021 was approximately ~~$90.5~~$79.3 million, of which ~~$76.7~~$63.9 million would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our consolidated statements of income.

The tax years subject to examination by major tax jurisdictions include ~~the~~ years ~~2012~~2017 and forward by the ~~IRS,~~U.S Internal Revenue Service (the “IRS”) as well as the years 2008 and forward for certain states and certain foreign jurisdictions. All tax returns audited by the IRS are officially closed through ~~2011. We are currently under audit~~2016. During the quarter ended June 26, 2021 we reached a resolution with the Appellate Division for ~~the years~~all remaining outstanding issues for 2012 and 2013. ~~In the quarter ended December 28, 2019, we~~The resolution did not have a material impact to our consolidated financial statements. We reached a settlement with the U.S. Competent Authority to resolve certain transfer pricing issues related to 2012 and ~~2013. For all remaining outstanding issues for 2012 and~~ 2013 ~~we have provided all necessary documentation to the Appellate Division to date and we currently expect resolution~~ in the ~~fourth~~ quarter ~~of 2020. We do not believe the final resolution will have a material impact to our consolidated financial statements.~~ended December 28, 2019. During the quarter ended September 26, 2020 we finalized negotiations with the Advance Pricing Division and reached an agreement on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution iswas to mitigate future transfer pricing audit adjustments. In the fourth quarter of 2020, we reached a favorable resolution with the IRS relating to select audit years.

The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest ~~expense~~ expense/(credit) was approximately ~~$(1.1)~~$(2.7) million for the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, and ~~$2.6~~$1.8 million for the ~~nine~~six months ended ~~September 28, 2019.~~June 27, 2020. The total amount of accrued interest is included in “Other ~~liabilities”,~~liabilities,” and was approximately ~~$16.2~~$11.3 million as of ~~September~~June 26, ~~2020~~2021 and ~~$18.0~~$14.0 million as of December ~~28, 2019.~~26, 2020. NaN penalties were accrued for the periods presented.

2925

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1514 – Derivatives and Hedging Activities

We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital.

During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Gains and losses related to these net investment hedges are recorded in Accumulated other comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our consolidated statements of income. The aggregate notional value of this net investment hedge, which matures on November 16, 2023, is approximately €200 million. During the three ~~and nine~~ months ended ~~September~~June 26, 2021 and June 27, 2020, we recognized approximately $1.1 million and $1.2 million, respectively, of interest savings as a result of this net investment hedge. During the six months ended June 26, 2021 and ~~$3.6~~June 27, 2020, we recognized approximately $2.2 and $2.4 million, respectively, of interest savings as a result of this net investment hedge.

On March 20, 2020, we entered into a total return swap for the purpose of ~~economic~~economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these plans was $43.4 million. At ~~September~~June 26, ~~2020,~~2021, the notional value of the investments in these plans was ~~$58.8~~$84.8 million. At ~~September~~June 26, ~~2020~~2021, the financing blended rate for this swap iswas based on LIBOR of ~~0.16%~~0.09% plus ~~0.38%~~0.47%, for a combined rate of ~~0.54%~~0.56%. ~~From March 20, 2020,~~For the ~~effective date~~three months and six months ended June 26, 2021, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $5.4 million and $8.1 million, respectively, net of transaction costs, related to this undesignated swap. For the ~~swap, to September 26,~~three months and six months ended June 27, 2020, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately ~~$3.8~~$6.7 million and ~~$14.2~~$10.3 million, respectively, net of transaction costs, related to this undesignated swap for the three and nine months ended September 26, 2020. This gain was offset by the change in fair value adjustment in deferred compensation, resulting in a neutral impact to our results of operations.swap. This swap is expected to be renewed on an annual ~~basis.~~basis after its current expiration date of March 29, 2022, and is expected to result in a neutral impact to our results of operations.

Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC 815 have been omitted.

3026

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1615 – Stock-Based Compensation

Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of ~~$5.7~~$17.4 million ($~~4.1~~13.3 million after-tax) and ~~a credit of $6.6~~$30.2 million ($~~5.3~~22.8 million after-tax) for the three and ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, respectively. For the three and ~~nine~~six months ended ~~September 28, 2019~~June 27, 2020 we recorded pre-tax share-based compensation expense of ~~$13.3~~$5.2 million ($~~10.2~~4.2 million after-tax) and ~~$33.1~~a credit of $12.4 million ($~~25.2~~9.4 million after-tax), respectively. The ~~$6.6~~$12.4 million credit for share-based compensation during the ~~nine~~six months ended ~~September 26,~~June 27, 2020 ~~reflects~~reflected our reduced estimate in expected achievement of performance-based targets resulting from the impact of COVID-19. Due to the significantly lower projected earnings in 2020, we are currently estimating that 0 performance shares granted under our 2018, 2019 or 2020 Long-Term Incentive Programs under our employee stock incentive plan will ultimately vest.

Our accompanying consolidated statements of cash flows present our stock-based compensation expense (credit) as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, there were 0 benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019,~~June 27, 2020, respectively.

Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense ~~on a straight-line basis~~ over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2020 Stock Incentive Plan ~~(formerly known as the 2013 Stock Incentive Plan),~~ and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of ~~Directors. Equity-based~~Directors (the “Compensation Committee”). Historically, equity-based awards ~~are~~have been granted solely in the form of restricted stock units ~~with~~(“RSUs”). However, beginning in 2021, our equity-based awards have been granted in the ~~exception~~form of ~~providing~~RSUs and non-qualified stock ~~options to employees pursuant to certain pre-existing contractual obligations.~~options.

Grants of ~~restricted stock units~~RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of ~~restricted stock units,~~RSUs, common stock is generally delivered on or following satisfaction of vesting conditions. We issue ~~restricted stock units~~RSUs that vest solely based on the recipient’s continued service over time (primarily ~~four year~~four-year cliff vesting, except for grants made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily ~~12 month~~12-month cliff vesting), and ~~restricted stock units~~RSUs that vest based on our achieving specified performance measurements and the recipient’s continued service over time (primarily ~~three year~~three-year cliff vesting). For these RSUs, we recognize the cost as compensation expense on a straight-line basis.

~~With respect~~During the three months ended March 27, 2021, as a result of the continuing economic risk and uncertainty resulting from the ongoing COVID-19 pandemic, the Compensation Committee decided to adjust the form of awards granted under our 2021 long-term incentive program for our 2021 fiscal year in a manner that focuses on our long-term value by granting stock options and time-based ~~restricted~~RSUs rather than performance-based RSUs. Stock options are awards that allow the recipient to purchase shares of our common stock ~~units, we estimate~~at a fixed price following vesting of the ~~fair value~~stock options. Stock options are granted at an exercise price equal to our closing stock price on the date of ~~grant~~grant. Stock options issued during 2021 vest one-third per year based on ~~our closing stock price. With respect~~the recipient’s continued service, subject to ~~performance-based restricted stock units,~~ the ~~number of shares that ultimately vest~~terms and ~~are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee~~conditions of the ~~Board~~Plans, are fully vested three years from the grant date and have a contractual term of ~~Directors. Although there~~ten years from the grant date, subject to earlier termination of the term upon certain events. Compensation expense for these stock options is ~~no guarantee that performance targets will be achieved, we~~recognized using a graded vesting method. We estimate the fair value of ~~performance-based restricted~~ stock ~~units based on our closing stock price at time of grant.~~options using the Black-Scholes valuation model.

3127

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

In addition to equity-based awards under the 2021 long-term incentive program under the 2020 Stock Incentive Plan, the Compensation Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive Plan to recipients of performance-based RSUs under the 2018 long-term incentive program. These awards will vest 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date and are recorded as compensation expense using a graded vesting method.

With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing stock price at time of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant.

The Plans provide for adjustments to the performance-based restricted stock units targets for significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes in ~~tax rates in certain countries, changes in~~ accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets and foreign exchange fluctuations. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.

As a result of the Separation, the number of our unvested (as of the date of the Separation) equity-based awards from previous grants made under our Long-term Incentive Program under the Plans was increased by a factor of approximately 1.2633, along with a corresponding ~~decrease~~ ~~in our price per share.~~

Total unrecognized compensation cost related to unvested awards as of ~~September~~June 26, ~~2020~~2021 was ~~$50.6~~$99.0 million, which is expected to be recognized over a weighted-average period of approximately ~~2.4~~2.5 years.

The following ~~tables summarize~~weighted-average assumptions were used in determining the ~~activity~~most recent fair values of ~~our unvested restricted stock/units for~~stock options using the ~~nine months ended September 26, 2020:~~Black-Scholes valuation model:

Time-Based Restricted Stock/Units

Weighted Average

Grant Date Fair

Intrinsic Value

Shares/Units

Value Per Share

Per Share
Outstanding at beginning of period

1,417

$
58.72

Granted

379

60.02

Vested

(297)

65.93

Forfeited

(47)

59.87

Outstanding at end of period

1,452

$
57.55

$
58.79

Performance-Based Restricted Stock/Units

Weighted Average

Grant Date Fair

Intrinsic Value

Shares/Units

Value Per Share

Per Share
Outstanding at beginning of period

1,459

$
61.41

Granted

(1,092)

55.89

Vested

(326)

67.51

Forfeited

(40)

57.84

Outstanding at end of period

1

$
52.10

$
58.79


Expected dividend yield	0.0	%
Expected stock price volatility	26.60	%
Risk-free interest rate	0.94	%
Expected life of options (years)	6.00

We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The 6-year expected life of the options was determined using the simplified method for estimating the expected term as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us.

3228

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The following table summarizes stock option activity under the Plans during the six months ended June 26, 2021:

				Weighted
				Average
		Weighted		Remaining
		Average		Contractual	Aggregate
		Exercise		Life in	Intrinsic
	Shares	Price		Years	Value
Outstanding at beginning of period	0	$	0
Granted	794		62.82
Exercised	0		0
Forfeited	(2)		62.71
Outstanding at end of period	792	$	62.82	9.7	$	12.21

Options exercisable at end of period	1	$	0	-	$	0

The following tables summarize the activity of our unvested RSUs for the six months ended June 26, 2021:

	Time-Based Restricted Stock Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,459	$	57.61
Granted	821		63.02
Vested	(266)		66.85
Forfeited	(19)		60.47
Outstanding at end of period	1,995	$	58.64	$	75.01

	Performance-Based Restricted Stock Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	136	$	53.52
Granted	286		58.60
Vested	(83)		52.30
Forfeited	(9)		59.46
Outstanding at end of period	330	$	59.50	$	75.01

Note 1716 – Supplemental Cash Flow Information

Cash paid for interest and income taxes was:

	Nine Months Ended				Six Months Ended
	September 26,		September 28,		June 26,		June 27,
	2020		2019		2021		2020
Interest	$	29,551	$	45,543	$	13,605	$	16,925
Income taxes		164,575		138,068		134,232		31,553

During the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019,~~June 27, 2020, we had a ~~$3.0~~$2.3 million and ~~$(2.0)~~$13.5 million of non-cash net unrealized ~~gain (loss)~~gains related to foreign currency hedging activities, respectively.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1817 – Legal Proceedings

On August 31, 2012, Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act. Archer ~~alleges~~alleged a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017, Archer filed an amended complaint, adding Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer ~~seeks~~sought damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive relief. On October 30, 2017, Archer filed a second amended complaint, to add additional allegations that it believes support its claims. The named parties and causes of action ~~are~~were the same as the August 1, 2017 amended complaint.

On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2) staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay. On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration. On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit denied that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020, which was subsequently moved to January 29, 2020. On January 24, 2020 the Supreme Court granted our motion to stay the District Court proceedings, pending the disposition of our petition for writ of certiorari, which was filed on January 31, 2020. Archer conditionally cross petitioned for certiorari on an arbitration issue on March 2, 2020. On June 15, 2020, the Supreme Court granted our petition for writ of certiorari, and denied Archer’s conditional petition for certiorari, and thus the District Court proceedings ~~remain~~remained stayed. ~~The~~After briefing from the parties and several amici, the case ~~is scheduled for argument~~was argued before the Supreme Court inon December 8, 2020. On January 25, 2021, the Supreme Court dismissed the writ of certiorari as improvidently granted. That action dissolved the stay the Supreme Court had previously granted. The U.S. District Court for the Eastern District of Texas then set the case for trial, and jury selection was scheduled to begin on June 1, 2021. Patterson and the Danaher Defendants settled with Archer and they have been dismissed from the case with prejudice. Benco settled

3330

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

the case with ~~prejudice. Benco is still a defendant and filed a notice of joinder in Henry Schein’s motion to compel arbitration with~~ the ~~District Court. We intend to defend ourselves vigorously against this action.~~

On March 7, 2018, Joseph Salkowitz, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Stanley M. Bergman and Steven Paladino in the U.S. District Court for the Eastern District of New York, Case No. 1:18-cv-01428. The complaint sought to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased Henry Schein securities from March 7, 2013 through February 12, 2018 (the “Class Period”). The complaint alleged, among other things, that the defendants had made materially false and misleading statements about Henry Schein’s business, operations and prospects during the Class Period, thereby causing the plaintiff and members of the purported class to pay artificially inflated prices for Henry Schein securities. Those alleged statements included matters relating to the issues in the In re Dental Supplies Antitrust Litigation, which Henry Schein settled and which the court dismissed in June 2019, and in the United States Federal Trade Commission (“FTC”) administrative proceeding, in which an administrative law judge ruled in Henry Schein’s favor in October 2019 after a trial, as described in our prior filings with the SEC. The complaint sought unspecified monetary damages and a jury trial. Pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), the court appointed lead plaintiff and lead counsel on June 22, 2018 and recaptioned the putative class action as In re Henry Schein, Inc. Securities Litigation, under the same case number. Lead plaintiff filed a consolidated class action complaint on September 14, 2018. The consolidated class action complaint asserted similar claims against the same defendants (plus Timothy Sullivan) on behalf of the same putative class of purchasers during the Class Period. It alleged that Henry Schein’s stock price had been inflated during that period because Henry Schein had misleadingly portrayed its dental-distribution business “as successfully producing excellent profits while operating in a highly competitive environment” even though, “in reality, [Henry Schein] had engaged for years in collusive and anticompetitive practices in order to maintain Schein’s margins, profits, and market share.” The complaint alleged that the stock price started to fall from August 8, 2017, when the company announced below-expected financial performance that allegedly “revealed that Schein’s poor results were a product of abandoning prior attempts to inflate sales volume and margins through anticompetitive collusion,” through February 13, 2018, after the FTC filed a complaint against Benco,plaintiff. Henry Schein and ~~Patterson alleging that they violated U.S. antitrust laws. The complaint alleged violations of Section 10(b) of~~ the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 and Section 20(a) of the Exchange Act. On September 27, 2019, the court issued a decision partially granting and partially denying defendants’ motion to dismiss the securities action. The court dismissed all claims against Messrs. Bergman and Paladino as well as the Section 10(b) claim against Henry Schein to the extent that that claim relied on the Company’s financial results and margins to allege a material misstatement or omission. The court also dismissed the Section 10(b) claim against Henry Schein to the extent that it relied on the Company’s August 8, 2017 disclosure to allege loss causation. The court otherwise denied the motion as to Henry Schein and Mr. Sullivan. Henry Schein and Mr. Sullivan moved for partial reconsideration of the court’s decision. Pursuant to all parties’ request, the court temporarily took the motion off the calendar after it was fully briefed. The parties later agreed to resolveplaintiff settled this matter ~~in exchange~~ for ~~a cash payment of $35 million, which would be covered by the Company’s insurance and would have no earnings impact~~an amount that is not material to the Company. The ~~Court held a fairness hearing~~court dismissed the case with prejudice on ~~the proposed settlement on September 16, 2020 and approved it later that day. The order and judgment approving the settlement have become final.~~May 25, 2021.

On May 3, 2018, a purported class action complaint, Marion Diagnostic Center, LLC, et al. v. Becton, Dickinson, and Co., et al., Case No. 3:18-cv-010509, was filed in the U.S. District Court for the Southern District of Illinois against Becton, Dickinson, and Co. (“Becton”); Premier, Inc. (“Premier”), Vizient, Inc. (“Vizient”), Cardinal Health, Inc. (“Cardinal”), Owens & Minor Inc. (“O&M”), Henry Schein, Inc., and Unnamed Becton Distributor Co-Conspirators. The complaint alleged that the defendants entered into a vertical conspiracy to force health care providers into long-term exclusionary contracts that restrain trade in the nationwide markets for conventional and safety syringes and safety IV catheters and inflate the prices of certain Becton products to above-competitive levels. The named plaintiffs sought to represent three separate classes consisting of all health care providers that purchased (i) Becton’s conventional syringes, (ii) Becton’s safety syringes, or (iii) Becton’s safety catheters directly from Becton, Premier, Vizient, Cardinal, O&M or Henry Schein on or after May 3, 2014. The complaint asserted a

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

single count under Section 1 of the Sherman Act, and sought equitable relief, treble damages, reasonable attorneys’ fees and costs and expenses, and pre-judgment and post-judgment interest. On June 15, 2018, an amended complaint was filed asserting the same allegations against the same parties and adding McKesson Medical-Surgical, Inc. as a defendant. On November 30, 2018, the District Court granted defendants’ motion to dismiss and entered a final judgment, dismissing plaintiffs’ complaint with prejudice. On December 27, 2018, plaintiffs appealed the District Court’s decision to the Seventh Circuit Court of Appeals. The parties argued the appeal on September 27, 2019. On March 5, 2020, the Seventh Circuit Court of Appeals reversed the District Court’s decision. The Seventh Circuit held that plaintiffs failed to adequately allege the necessary conspiracy by the defendants, but should be provided an opportunity to amend their complaint. The Seventh Circuit vacated the District Court’s judgment, and remanded the case for further proceedings consistent with its opinion. Plaintiffs subsequently dropped Henry Schein as a defendant in their amended complaint.

On May 29, 2018, an amended complaint was filed in the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) in an action entitled The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al., Civil Action No. 1:18-op-45090-DAP (“County of Summit Action”), in the U.S. District Court for the Northern District of Ohio, adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants. Summit County alleged that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $1 million to a foundation and paid $250,000 of Summit County’s expenses, as described in our prior filings with the SEC.

In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have been named as a defendant in multiple lawsuits (currently less than one-hundred and fifty (150)), which allege claims similar to those alleged in the County of Summit Action. These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. On October 9, 2020, the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida, Case No. CACE19018882, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by North Broward Hospital District et. al. The Florida court gave plaintiffs until ~~October 29,~~November 24, 2020 to replead their claims against Henry Schein. On January 8, 2021, Henry Schein filed a motion to dismiss the Amended Complaint. By Order entered on March 24, 2021, the Circuit Court of Washington County, Arkansas, Case No. 72-CV20-156, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by Fayetteville Arkansas Hospital Company, LLC, et al. The Arkansas plaintiffs ~~have asked the Florida court for~~filed an ~~additional 20 days to replead their claims.~~amended complaint on July 29, 2021and did not name Henry Schein as a defendant. An action filed by Tucson Medical Center et al. was previously scheduled for trial beginning on June 1, 2021 but the court has vacated that trial date. At this time, the only ~~case~~cases set for trial isare the ~~action~~actions filed by West Virginia University Hospitals, Inc. et al., which is currently scheduled for a non-jury liability trial on ~~Plaintiffs’~~plaintiffs’ public nuisance claims on November 1, ~~2021.~~2021, and DCH Health Care Authority, et al., which is currently scheduled for a liability jury trial on plaintiffs’ public nuisance claims on July 18, 2022. Of Henry Schein’s ~~2019~~2020 revenue of approximately ~~$10~~$10.1 billion from continuing operations, sales of opioids represented less than one-tenth of 1 ~~percent~~. percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.

On September 30, 2019, the City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from

3531

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Securities Exchange Act of 1934, as amended, and Securities and Exchange Commission Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary damages and a jury trial. Pursuant to the provisions of the PSLRA, the court appointed lead plaintiff and lead counsel on December 23, 2019. Lead plaintiff filed a Consolidated Class Action Complaint on February 21, 2020. Lead plaintiff added Steve Paladino, our Chief Financial Officer, as a defendant in the action. Lead plaintiff filed an Amended Consolidated Class Action Complaint on May 21, 2020, in which it added a claim that Mr. Paladino is a “control person” of Covetrus. We intend to defend ourselves vigorously against this action.

On ~~November 15, 2019, Frank Finazzo~~February 5, 2021, Jack Garnsey filed a putative shareholder derivative action on behalf of ~~Henry Schein,~~Covetrus, Inc. ~~against various present and former directors and officers of Henry Schein~~ in the U.S. District Court for the Eastern District of New York, ~~Case No. 1:19-cv-6485-LDH-JO. The named~~naming as defendants ~~in the action are Stanley M. Bergman,~~Benjamin Shaw, Christine T. Komola, Steven Paladino, ~~Timothy J. Sullivan, Barry J. Alperin, Lawrence S. Bacow, Gerald A. Benjamin, James P. Breslawski, Paul Brons, Shira Goodman, Joseph~~Betsy Atkins, Deborah G. Ellinger, Sandra L. ~~Herring, Donald J. Kabat, Kurt Kuehn,~~Helton, Philip A. ~~Laskawy, Anne H. Margulies, Karyn Mashima, Norman S. Matthews,~~Laskaway, Mark J. Manoff, Edward M. McNamara, Ravi Sachdev, David E. ~~Mlotek, Carol Raphael, E. Dianne Rekow, Bradley T. Sheares,~~Shaw, Benjamin Wolin, and ~~Louis W. Sullivan, with~~ Henry Schein, Inc., with Covetrus, Inc. named as a nominal defendant. The ~~Complaint asserts claims~~complaint alleges that the individual defendants breached their fiduciary duties under ~~the federal securities laws and~~ state law ~~relating to~~in connection with the same allegations asserted in ~~the antitrust actions, the In re Henry Schein, Inc. Securities Litigation, and~~ the City of Hollywood securities class action described ~~above.~~above and further alleges that Henry Schein aided and abetted such breaches. The complaint also asserts claims for contribution under the federal securities laws against Henry Schein and other defendants, also arising out of the allegations in the City of Hollywood lawsuit. The complaint seeks declaratory, injunctive, and monetary ~~relief on behalf of Henry Schein.~~relief. We intend to defend ourselves vigorously against this action. On ~~January 6, 2020, counsel who filed~~April 8, 2021 the ~~Finazzo case filed another, virtually identical putative shareholder derivative~~Court entered an order staying the Garnsey action ~~on behalf of Henry Schein against~~until forty-five (45) days after a decision is issued finally resolving the ~~same defendants, asserting the same claims and seeking the same relief. That case, captioned Mark Sloan v. Stanley M. Bergman, et al., is also pending~~motions to dismiss in the ~~U.S. District Court for the Eastern District~~City of New York, Case No. 1:20-cv-0076. On January 24, 2020, the court consolidated the Finazzo and Sloan cases under the new caption In re Henry Schein, Inc. Derivative Litigation, No. 1:19-cv-06485-LDH-JO, and appointed the counsel in these cases as co-lead counsel for the consolidated action. The parties agreed to a resolution of this matter subject to various conditions, including court approval. The contemplated settlement, if finally approved, would involve the adoption of certain procedures but would not involve the payment of any money except a fee to the plaintiffs’ attorneys that is immaterial. The Court preliminarily approved the proposed settlement on June 10, 2020, and scheduled a fairness hearing for September 22, 2020. On September 9, 2020, the Court issued an order referring the motion for final settlement approval and fairness hearing to a Magistrate Judge for a report and recommendation. On September 10, 2020, the Magistrate Judge issued an order adjourning the September 22, 2020 fairness hearing without setting a new date. The parties have consented to the cases being assigned to the Magistrate Judge for all purposes.Hollywood Class Action.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations.

As of ~~September~~June 26, ~~2020,~~2021, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Note 1918 – Related Party Transactions

On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus. In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors for $361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”).

In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, ~~2019,~~ we entered into a transition services agreement with Covetrus under which we ~~have~~ agreed to provide certain transition services for up to 24twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services. Services provided under this transition services agreement ended in December 2020. During the three and ~~nine~~six months ended ~~September 26,~~June 27, 2020, we recorded approximately $~~3.9~~$4.3 million and ~~$12.7 million, respectively, of fees for these services. During the three and nine months ended September 28, 2019, we recorded approximately $4.7 million and $13.0~~$8.8 million, respectively, of fees for these services. Covetrus also ~~purchases~~purchased certain products from us pursuant to the transition services ~~agreement.~~agreement, which ended in December 2020. During the three and ~~nine~~six months ended ~~September 26,~~June 27, 2020, net sales to Covetrus were approximately ~~$24.8~~$20.1 million and ~~$66.0~~$41.2 million, respectively. During the three and nine months ended September 28, 2019, net sales to Covetrus were approximately $21.8 million and $60.2 million, respectively. Sales to Covetrus under the transition services agreement have been substantially completed as of October 2020. At September 26, 2020 we had $4.2 million of receivables due from Covetrus and $0.4 million payable to Covetrus under this transition services agreement.

In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ~~ten year~~ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately ~~$31.0~~$31.0 million annually for the use of their intellectual property. During the three and ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, we recorded $7.8 million and ~~$23.4~~$15.6 million, respectively in connection with costs related to this royalty agreement. During the three and ~~nine~~six months ended ~~September 28, 2019,~~June 27, 2020, we recorded $7.8 million and ~~$23.4~~$15.6 million, respectively in connection with costs related to this royalty agreement. As of ~~September~~June 26, ~~2020~~2021 and December ~~28, 2019,~~26, 2020, Henry Schein One, LLC had a net (payable) receivable balance due (to) from Internet Brands of ~~$13.5~~$(6.3) million and ~~$9.8~~$4.7 million, respectively, comprised of amounts related to results of operations and the royalty agreement.

During our normal course of business, we have interests in entities that we account for under the equity accounting method. During the three and ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, we recorded net sales of ~~$10.0~~$18.0 million and ~~$33.1~~$33.4 million, respectively, to such entities. During the three and ~~nine~~six months ended ~~September 28, 2019,~~June 27, 2020, we recorded net sales of ~~$28.6~~$9.1 million and ~~$74.4~~$24.5 million, respectively, to such entities. During the three and ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, we purchased ~~$2.9~~$5.3 million and ~~$7.7~~$9.1 million, respectively, from such entities. During the three and ~~nine~~six months ended ~~September 28, 2019,~~June 27, 2020, we purchased ~~$3.2~~$1.7 million and ~~$9.0~~$4.5 million, respectively, from such entities. At ~~September~~June 26, 2021 and December 26, 2020, ~~and December 28, 2019,~~in the aggregate we had ~~in aggregate $34.3~~$42.0 million and ~~$30.8~~$36.4 million, due from our equity affiliates, and ~~$6.9~~$10.1 million and ~~$4.9~~$8.6 million due to our equity affiliates, respectively.

3733

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in ~~this Quarterly Report on Form 10-Q, and in particular~~ the ~~risks discussed under the caption “Risk Factors” in Item 1A of this report and those discussed in other~~ documents we file with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity, and financial condition (including any estimates of the ~~percentage~~ impact on these items), the rate and consistency with which dental and other practices resume or maintain normal operations in the United States and internationally, expectations regarding ~~PPE~~personal protective equipment (“PPE”) and ~~other~~ COVID-19 related product sales and inventory levels and whether ~~one~~additional resurgences or ~~more resurgences~~variants of the virus will adversely impact the resumption of normal operations, the impact of restructuring programs as well as of any future acquisitions, and more generally current expectations regarding performance in current and future periods. Forward looking statements also include the ~~Company’s~~(i) ability of the Company to make additional testing available, the nature of those tests and the number of tests intended to be made available and the timing for availability, the nature of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been, or will not have been, independently verified under normal FDA ~~procedures.~~procedures and (ii) potential for the Company to distribute the COVID-19 vaccines and ancillary supplies.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: ~~effects~~risks associated with COVID-19 and any variants thereof, as well as other disease outbreaks, epidemics, pandemics, or similar wide spread public health concerns and other natural disasters or acts of ~~a highly competitive and consolidating market; increased competition by third party online commerce sites;~~terrorism; our dependence on third parties for the manufacture and supply of our products; our ~~dependence upon sales personnel, customers, suppliers~~ability to develop or acquire and ~~manufacturers;~~maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions in our ~~dependence~~governing documents that may discourage third-party acquisitions of us; effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; the potential repeal or judicial prohibition on ~~our senior management; fluctuations~~implementation of the Affordable Care Act; changes in ~~quarterly earnings;~~the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic ~~conditions; risks associated with currency fluctuations; risks associated with~~and political conditions, including international trade agreements and ~~economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws;~~potential trade barriers; failure to comply with existing and future regulatory requirements and data privacy laws; risks associated with our global operations; risks associated with COVID-19, as well as other disease outbreaks, epidemics, pandemics, or similar wide spread public health concerns and other natural disasters;requirements; risks associated with the ~~United Kingdom’s withdrawal from the European Union; transitional challenges associated with acquisitions, dispositions and joint ventures, including the~~ EU Medical Device Regulation; failure to ~~achieve anticipated synergies/benefits; financial~~comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the confidentiality of sensitive personal information or standards in electronic health records or transmissions; changes in tax ~~risks associated with acquisitions, dispositions and joint ventures;~~legislation; litigation risks; new or unanticipated litigation developments and the status of litigation matters; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence on third parties for certain technologically advanced components; risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; ~~certain provisions~~risks associated with our global operations; our dependence on our senior management, as well as employee hiring and retention; and disruptions in ~~our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation.~~financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

Table of Contents

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

~~Table of Contents~~

Where You Can Find Important Information

We may disclose important information through one or more of the following channels: SEC filings, public conference calls and webcasts, press releases, the investor relations page of our website (~~www.henryschein.com~~)(www.henryschein.com) and the social media channels identified on the Newsroom page of our website.

Recent Developments

COVID-19 Pandemic

In March 2020, the World Health Organization declared ~~the Novel Coronavirus Disease 2019 (“COVID-19”)~~COVID-19 a pandemic. The COVID-19 pandemic ~~has~~ negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. Demand increased in the ~~third quarter~~second half of 2020 and continued into the first half of 2021, resulting in growth over the prior year driven by sales of ~~personal protective equipment (PPE)~~PPE and COVID-19 related products.

Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and indefinite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a material adverse effect on our business, results of operations and cash flows in the second quarter of 2020. In the latter half of the second quarter of 2020, dental and medical practices began to re-open worldwide, and continued to do so during the ~~third quarter. However,~~second half of 2020. During the first half of 2021, patient ~~volumes remain below pre-COVID-19~~traffic levels ~~and certain regions in the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there~~returned to levels approaching pre-pandemic levels. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.

As part of a broad-based effort to support plans for the long-term health of our business and to strengthen our financial flexibility, we implemented cost reduction measures that included certain reductions in payroll, substantially decreased capital expenditures, reduced corporate spending and elimination of certain non-strategic targeted expenditures. As our markets have begun to recover we have ended most of those temporary expense-reduction initiatives during the third quarter.

~~Corporate Transactions~~

On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”) (the “Merger”). This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale Investors”) for $361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the

3935

Table of Contents

Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted basis, (i) approximately 63% of the shares of Covetrus common stock were (a) owned by our stockholders and the Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form of certain equity awards), and (ii) approximately 37% of the shares of Covetrus common stock were (a) owned by stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger, Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market.

Executive-Level Overview

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. We believe we are the world’s largest provider of health care products and services primarily to office-based dental and medical ~~practitioners.~~practitioners, as well as alternate sites of care. We serve more than one million customers worldwide including dental practitioners and laboratories and physician practices, as well as government, institutional health care clinics and other alternate care clinics. We believe that we have a strong brand identity due to our more than 88 years of experience distributing health care products.

We are headquartered in Melville, New York, employ ~~more than 19,000~~approximately 21,000 people (of which more than ~~9,500~~10,200 are based outside the United States) and have operations or affiliates in 3132 countries and territories, including the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, Mexico, the Netherlands, New Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom.

We have established strategically located distribution centers around the world to enable us to better serve our customers and increase our operating efficiency. This infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our customers’ needs. Our infrastructure also allows us to provide convenient ordering and rapid, accurate and complete order fulfillment.

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base.

Industry Overview

In recent years, the health care industry has increasingly focused on cost ~~containment and on value-based reimbursement arrangements that condition payment to health care providers on the achievement of cost savings and quality targets.~~containment. This trend has benefited distributors capable of providing a broad array of products and services at low prices. It also has accelerated the growth of HMOs, group practices, other managed care ~~arrangements~~accounts and collective buying groups, which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing specialized management information support. We believe that the trend towards cost containment ~~and value-based reimbursement~~ has the potential to favorably affect demand for

~~Table of Contents~~

technology solutions, including software, which can enhance the efficiency and facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies and transactions that we undertook to expand our business, domestically and internationally, in part to address significant changes in the health care industry, including consolidation of health care distribution companies, health care reform, trends toward managed care, cuts in Medicare and collective purchasing arrangements.

Our current and future results have been and could ~~continue to~~ be ~~adversely~~ impacted by the COVID-19 pandemic, the current economic environment and ~~uncertainty, particularly impacting overall~~continued economic and public health uncertainty. Since the onset of the COVID-19 pandemic in early 2020, we have been carefully monitoring its impact on our global operations and have taken appropriate steps

Table of Contents

to minimize the risk to our employees. We have seen and continue to see changes in demand trends for some of our products and ~~services.~~services as rates of infection fluctuate, new strains or variants of COVID-19 emerge and spread, vaccine uptake increases, governments adapt their approaches to combatting the virus, and local conditions change across geographies. As a result, we expect to see continued volatility through at least the duration of the pandemic.

Industry Consolidation

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices or service organizations ranging in size from a few practitioners to a large number of practitioners who have combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or professional staff level; however, orders are delivered to the practitioners’ offices.

We believe that consolidation within the industry will continue to result in a number of distributors, particularly those with limited financial, operating and marketing resources, seeking to combine with larger companies that can provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire companies that can enhance their current product and service offerings or provide opportunities to serve a broader customer base.

Our trend with regard to acquisitions and joint ventures has been to expand our role as a provider of products and services to the health care industry. This trend has resulted in our expansion into service areas that complement our existing operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.

As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we have the ability to support increased sales through our existing infrastructure, although there can be no assurances that we will be able to successfully accomplish this. We also have invested in expanding our sales/marketing infrastructure to include a focus on building relationships with decision makers who do not reside in the office-based practitioner setting.

As the health care industry continues to change, we continually evaluate possible candidates for merger and joint venture or acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to the health care industry. There can be no assurance that we will be able to successfully pursue any such opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the integration efforts associated with any such transaction would be successful. In response to the COVID-19 pandemic, we had taken a range of actions to preserve cash, including the temporary suspension of significant acquisition activity. During the ~~third quarter~~second half of 2020, as global conditions improved, we resumed our acquisition strategy.

4137

Table of Contents

Aging Population and Other Market Influences

The health care products distribution industry continues to experience growth due to the aging population, increased health care awareness, the proliferation of medical technology and testing, new pharmacology treatments and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing from acute care settings to alternate-care sites, particularly physicians’ offices.

According to the U.S. Census Bureau’s International Data Base, in ~~2020~~2021 there were more than six and a ~~half`~~half million Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care services. By the year 2050, that number is projected to nearly triple to approximately 19 million. The population aged 65 to 84 years is projected to increase by approximately ~~36%~~32% during the same time period.

As a result of these market dynamics, annual expenditures for health care services continue to increase in the United States. We believe that demand for our products and services will grow, while continuing to be impacted by current and future operating, economic and industry conditions. The Centers for Medicare and Medicaid Services, or CMS, published “National Health Expenditure Projections 2019-2028” indicating that total national health care spending reached approximately ~~$3.6~~$3.8 trillion in ~~2018,~~2019, or 17.7% of the nation’s gross domestic product, the benchmark measure for annual production of goods and services in the United States. Health care spending is projected to reach approximately $6.2 trillion in 2028, approximately 19.7% of the nation’s projected gross domestic product.

Government

Certain of our businesses involve the distribution, importation, exportation, marketing and sale of, and third party payment for, pharmaceuticals and medical devices, and in this regard, we are subject to extensive local, state, federal and foreign governmental laws and regulations, including as applicable to ~~the~~our wholesale distribution ~~and sale~~ of pharmaceuticals and medical ~~devices. Additionally,~~devices, and as part of our specialty home medical supply business that distributes and sells medical equipment and supplies directly to patients. The federal government and state governments have also increased enforcement activity in the health care sector, particularly in areas of fraud and abuse, anti-bribery and corruption, controlled substances handling, medical device regulations, and data privacy and security standards.

Government and private insurance programs fund a large portion of the total cost of medical care, and there ~~has~~have been ~~an emphasis on~~ efforts to limit such private and government insurance programs, including efforts, thus far unsuccessful, to seek repeal of the entire United States Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010, as amended. In addition, activities to control medical costs, including laws and regulations lowering reimbursement rates for pharmaceuticals, medical devices, and/or medical treatments or ~~services. Also, many~~services, are ongoing. Many of these laws and regulations are subject to change and their evolving implementation may impact our operations and our financial performance. ~~For example, certain laws and regulations restricting medical supply sales in the United States have been temporarily modified or waived in response to the COVID-19 pandemic. In addition, our~~

Our businesses are also generally subject to numerous other laws and regulations that could impact our financial performance, including securities, antitrust, consumer protection, anti-bribery and anti-kickback, customer interaction transparency, data privacy, data security, government contracting, price gouging, and other laws and ~~regulations, and some of the related rules have been temporarily modified in response to the COVID-19 pandemic.~~ regulations.

Failure to comply with law or regulations could have a material adverse effect on our business. A more detailed discussion of governmental laws and regulations is included in Management’s Discussion & Analysis, contained in our Annual Report on Form 10-K for the fiscal year ended December 28 2019, filed on February 20, 2020.

4238

Table of Contents

Results of Operations

The following table summarizes the significant components of our operating results for the three and ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020 and cash flows for the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020 (in thousands):

			Three Months Ended				Nine Months Ended						Three Months Ended				Six Months Ended
			September 26,		September 28,		September 26,		September 28,				June 26,		June 27,		June 26,		June 27,
			2020		2019		2020		2019				2021		2020		2021		2020
Operating results:	Operating results:										Operating results:
Net sales	Net sales		$	2,840,146	$	2,508,767	$	6,953,416	$	7,316,862	Net sales		$	2,967,223	$	1,684,399	$	5,892,184	$	4,113,270
Cost of sales	Cost of sales			2,085,847		1,747,600		4,998,784		5,036,574	Cost of sales			2,077,472		1,230,133		4,111,582		2,912,990
	Gross profit			754,299		761,167		1,954,632		2,280,288	Gross profit			889,751		454,266		1,780,602		1,200,280
Operating expenses:	Operating expenses:										Operating expenses:
	Selling, general and administrative			559,636		574,771		1,572,816		1,742,597	Selling, general and administrative			678,801		445,765		1,336,793		1,013,127
	Restructuring costs (credits)			6,992		(802)		27,713		15,764	Restructuring costs			604		15,934		3,535		20,721
		Operating income	$	187,671	$	187,198	$	354,103	$	521,927		Operating income (loss)	$	210,346	$	(7,433)	$	440,274	$	166,432

Other expense, net	Other expense, net		$	(10,516)	$	(8,607)	$	(24,138)	$	(31,103)	Other expense, net		$	(4,665)	$	(8,780)	$	(8,858)	$	(13,622)
Net income from continuing operations				151,813		143,212		271,808		388,269
Income (loss) from discontinued operations				(29)		5,641		274		(5,210)
Net income attributable to Henry Schein, Inc.				141,697		140,557		261,161		364,872
Net income (loss) from continuing operations											Net income (loss) from continuing operations			163,977		(13,852)		338,905		119,995
Income from discontinued operations											Income from discontinued operations			-		585		-		303
Net income (loss) attributable to Henry Schein, Inc.											Net income (loss) attributable to Henry Schein, Inc.			155,716		(10,797)		321,713		119,464

							Nine Months Ended										Six Months Ended
							September 26,		September 28,								June 26,		June 27,
							2020		2019								2021		2020
Cash flows:	Cash flows:										Cash flows:
Net cash provided by operating activities from continuing operations							$	248,414	$	525,180
Net cash provided by (used in) operating activities from continuing operations											Net cash provided by (used in) operating activities from continuing operations						$	221,726	$	(12,843)
Net cash used in investing activities from continuing operations	Net cash used in investing activities from continuing operations							(93,956)		(691,349)	Net cash used in investing activities from continuing operations							(341,119)		(69,641)
Net cash provided by financing activities from continuing operations								264,433		176,139
Net cash provided by (used in) financing activities from continuing operations											Net cash provided by (used in) financing activities from continuing operations							(139,395)		262,050

Plans of Restructuring

4339

Table of Contents

Three Months Ended ~~September~~June 26, ~~2020~~2021 Compared to Three Months Ended ~~September 28, 2019~~June 27, 2020

Net Sales

Net sales for the three months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020 were as follows (in thousands):

			September 26,		% of		September 28,		% of		Increase						June 26,		% of		June 27,		% of		Increase / (Decrease)
			2020		Total		2019		Total		$		%				2021		Total		2020		Total		$		%
Health care distribution ⁽¹⁾	Health care distribution ⁽¹⁾														Health care distribution ⁽¹⁾
	Dental		$	1,649,853	58.1	%	$	1,545,981	61.6	%	$	103,872	6.7	%	Dental		$	1,910,344	64.4	%	$	941,292	55.9	%	$	969,052	102.9	%
	Medical			1,027,146	36.2			803,709	32.0			223,437	27.8		Medical			904,828	30.5			617,810	36.7			287,018	46.5
		Total health care distribution		2,676,999	94.3			2,349,690	93.6			327,309	13.9			Total health care distribution		2,815,172	94.9			1,559,102	92.6			1,256,070	80.6
Technology and value-added services ⁽²⁾	Technology and value-added services ⁽²⁾			138,355	4.9			137,334	5.5			1,021	0.7		Technology and value-added services ⁽²⁾			152,051	5.1			105,227	6.2			46,824	44.5
		Total excluding Corporate TSA revenue		2,815,354	99.2			2,487,024	99.1			328,330	13.2			Total excluding Corporate TSA revenue		2,967,223	100.0			1,664,329	98.8			1,302,894	78.3
Corporate TSA revenue ⁽³⁾	Corporate TSA revenue ⁽³⁾			24,792	0.8			21,743	0.9			3,049	14.0		Corporate TSA revenue ⁽³⁾			-	-			20,070	1.2			(20,070)	-
		Total	$	2,840,146	100.0	%	$	2,508,767	100.0	%	$	331,379	13.2			Total	$	2,967,223	100.0	%	$	1,684,399	100.0	%	$	1,282,824	76.2

(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.

The ~~13.2%~~76.2% increase in net sales for the three months ended ~~September~~June 26, ~~2020~~2021 includes an increase of ~~13.1%~~71.0% in local currency revenue ~~(13.0%~~(65.5% increase in internally generated revenue and ~~0.1%~~5.5% growth from acquisitions) and an increase of ~~0.1%~~5.2% related to foreign currency exchange. During December 2020, our previous transition services agreement (TSA) with Covetrus, in connection with the completion of the Animal-Health Spin-off, concluded. Accordingly, we recorded no Corporate TSA revenues for the three months ended June 26, 2021. Sales infor the ~~third quarter~~three months ended June 26, 2021 benefited from ~~an approximate 291% increase in~~ sales of ~~personal protection equipment (PPE)~~PPE and ~~other~~ COVID-19 related products of approximately $354.2 million, an increase of 76.0% versus the prior year. Excluding PPE and COVID-19 related products, the increase in internally generated local currency dental sales was 66.2%. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which ~~accounts~~significantly impacted global business and dramatically reduced demand for ~~nearly all~~dental products and certain medical products in the ~~growth~~second quarter of 2020. On a comparable basis to the three months ended June 29, 2019, our net sales for the three months ended June 26, 2021 increased by 15.2% in ~~sales.~~local currency.

The ~~6.7%~~102.9% increase in dental net sales for the three months ended ~~September~~June 26, ~~2020~~2021 includes an increase of ~~6.6%~~94.3% in local currency revenue ~~(6.5%~~(87.0% increase in internally generated revenue and ~~0.1%~~7.3% growth from acquisitions) and an increase of ~~0.1%~~8.6% related to foreign currency exchange. The ~~6.6%~~94.3% increase in local currency sales was attributable to an increase in dental consumable merchandise sales of ~~9.4% (9.3%~~99.7% (90.5% increase in internally generated revenue and ~~0.1%~~9.2% growth from acquisitions)~~, partially offset by a decrease~~ and an increase in dental equipment sales and service revenues of ~~2.6%~~76.3%, ~~all of which is attributable to the decrease~~(75.3% increase in internally generated revenue. Dental equipment sales in the third quarter continued to recover as internal sales in local currencies in North America were essentially flat. International dental equipment sales experienced only a slight decline as practices resumed investments in traditionalrevenue and ~~high-technology capital equipment solutions. Although the~~1.0% growth from acquisitions). The COVID-19 pandemic ~~adversely impacted our worldwide revenue beginning in mid-March as many~~had an adverse impact on prior year revenues when dental offices ~~progressively closed~~began closing or ~~began~~ seeing a limited number of patients ~~our dental sales began to improve~~beginning in mid-March of 2020. However, in the second half of the quarter ended June 27, 2020 ~~and continuing into the quarter ended September 26, 2020~~our dental sales began to improve as dental practices ~~resumed operating~~began to resume activities and patient traffic increased. ~~Global~~During the second quarter of 2021, patient traffic levels continued to return to levels approaching pre-pandemic levels, thus contributing to growth in worldwide dental revenues. Additionally, dental sales infor the ~~third quarter~~three months ended June 26, 2021 benefited from ~~an approximate 130% increase in~~ sales of PPE ~~which accounts~~and COVID-19 related products of approximately $181.8 million, an increase of 87.6% versus the prior year. Excluding PPE and COVID-19 related products, the increase in internally generated local currency dental sales was 90.8%. On a comparable basis to the three months ended June 29, 2019, our dental net sales for ~~nearly all~~ the ~~growth~~three months ended June 26, 2021 increased by 12.1% in ~~dental sales.~~local currency.

Table of Contents

The ~~27.8%~~46.5% increase in medical net sales for the three months ended ~~September~~June 26, ~~2020~~2021 includes an increase of ~~27.7%~~46.1% in local currency revenue (43.5% increase in internally generated revenue and 2.6% growth from acquisitions) and an increase of ~~0.1%~~0.4% related to foreign currency exchange. The COVID-19 pandemic began to adversely impact our medical revenue beginning in mid-March 2020 and in the first half of the second quarter of 2020, as many medical offices closed or saw a limited number of patients. Economic conditions relating to the COVID-19 pandemic ~~have~~ had less of an impact on the performance of our medical group ~~versus dental,~~in the prior year in part due to continued strong sales of PPE, such as masks, gowns and face shields, and other COVID-19 related products, ~~such as diagnostic test kits. Globally, our~~which have continued to be strong in the current year. Our medical business ~~experienced growth of~~recorded sales of $172.4 million of such PPE and other COVID-19 related products ~~by approximately 600%~~for the three months ended June 26, 2021, an increase of 65.3% compared to the prior ~~year, which accounts~~year. Excluding sales of PPE and other COVID-19 related products, medical internal sales in local currencies increased by 39.1%. On a comparable basis to the three months ended June 29, 2019, our medical net sales for ~~nearly all~~ the ~~growth~~three months ended June 26, 2021 increased by 27.2% in ~~medical sales.~~local currency.

The ~~0.7%~~44.5% increase in technology and value-added services net sales for the three months ended ~~September~~June 26, ~~2020~~2021 includes an increase of ~~0.3%~~41.9% local currency revenue ~~(1.3% decrease~~(33.0% increase in internally generated revenue ~~partially offset by 1.6%~~and 8.9% growth from acquisitions) and an increase of ~~0.4%~~2.6% related to foreign currency exchange. Sales growth was driven by our practice management business, as well as strong financial services revenue, which benefited from dental equipment sales growth. During the

~~Table of Contents~~

quarter ~~in line with the resumption of dental practice operations,~~ended June 26, 2021, the trend for transactional software revenues improved compared to the prior year, as more patients visited dental practices worldwide. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which significantly impacted transactional software revenues. On a comparable basis to the three months ended June 29, 2019, our technology and value-added services net sales for the three months ended June 26, 2021 increased by 10.1% in local currency.

Although dental and medical practices continued to re-open during the third quarter, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our net sales in future periods.

Gross Profit

Gross profit and gross margin percentages by segment and in total for the three months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020 were as follows (in thousands):

		September 26,		Gross		September 28,		Gross		Increase / (Decrease)					June 26,		Gross		June 27,		Gross		Increase / (Decrease)
		2020		Margin %		2019		Margin %		$		%			2021		Margin %		2020		Margin %		$		%
Health care distribution	Health care distribution	$	653,204	24.4	%	$	659,955	28.1	%	$	(6,751)	(1.0)	%	Health care distribution	$	784,841	27.9	%	$	381,042	24.4	%	$	403,799	106.0	%
Technology and value-added services	Technology and value-added services		100,272	72.5			100,557	73.2			(285)	(0.3)		Technology and value-added services		104,910	69.0			72,683	69.1			32,227	44.3
	Total excluding Corporate TSA revenues		753,476	26.8			760,512	30.6			(7,036)	(0.9)		Total excluding Corporate TSA revenues		889,751	30.0			453,725	27.3			436,026	96.1
Corporate TSA revenues	Corporate TSA revenues		823	3.3			655	3.0			168	25.6		Corporate TSA revenues		-	-			541	2.7			(541)	-
	Total	$	754,299	26.6		$	761,167	30.3		$	(6,868)	(0.9)		Total	$	889,751	30.0		$	454,266	27.0		$	435,485	95.9

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in research and development.

InDuring December 2020, our previous transition services agreement with Covetrus, in connection with the completion of the ~~Animal Health~~Animal-Health Spin-off, ~~(see~~ ~~Note 2-Discontinued Operations~~ ~~of the Notes~~concluded. Under this agreement, Covetrus had agreed to ~~the Consolidated Financial Statements included under Item 1 for additional details), we entered into a transition services agreement with Covetrus, pursuant to which Covetrus purchases~~purchase certain products from ~~us. The agreement provides that these products will be sold to Covetrus~~us at a mark-up that ~~ranges~~ranged from 3% to 6% of our product cost to cover handling costs. ~~These sales~~

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting our gross profit margin. For example, sales of pharmaceutical products are generally at lower gross profit margins than other products. Conversely, sales of our private label products achieve gross profit margins that are higher than average. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who normally purchase lower volumes at greater frequencies.

Table of Contents

Health care distribution gross profit increased $403.8 million, or 106.0%, for the three months ended June 26, 2021 compared to the prior year period, due primarily to the increase in net sales discussed above. Health care distribution gross profit margin increased to 27.9% for the three months ended June 26, 2021 from 24.4% for the comparable prior year period due primarily to lower adjustments recorded for PPE inventory. Such adjustments to inventory may recur and adversely impact gross profit margins in future periods, although we do not expect further material inventory adjustments in 2021. The increase in health care distribution gross profit margin is also attributable to an increase in vendor rebates during the second quarter of 2021 due to increased purchase volumes. The overall increase in our health care distribution gross profit is attributable to an increase of $298.9 million from internally generated revenue, a $78.3 million increase in gross profit due to the increase in the gross margin rates and a $26.6 million increase in gross profit from acquisitions.

Technology and value-added services gross profit increased $32.2 million, or 44.3%, for the three months ended June 26, 2021 compared to the prior year period. The overall increase in our Technology and value-added services gross profit is attributable to a $25.8 million increase in internally generated revenue and $6.8 million additional gross profit from acquisitions, partially offset by a decrease of $0.4 million from gross margin rates. Technology and value-added services gross profit margin decreased to 69.0% for the three months ended June 26, 2021 from 69.1% for the comparable prior year period.

Selling, General and Administrative

Selling, general and administrative expenses by segment and in total for the three months ended June 26, 2021 and June 27, 2020 were as follows (in thousands):

				% of				% of
		June 26,		Respective		June 27,		Respective		Increase
		2021		Net Sales		2020		Net Sales		$		%
Health care distribution		$	603,080	21.4	%	$	406,931	26.1	%	$	196,149	48.2	%
Technology and value-added services			76,325	50.2			54,768	52.0			21,557	39.4
	Total	$	679,405	22.9		$	461,699	27.4		$	217,706	47.2

Selling, general and administrative expenses (including restructuring costs in the three months ended June 26, 2021 and June 27, 2020) increased $217.7 million, or 47.2%, for the three months ended June 26, 2021 from the comparable prior year period. In the prior year, there were significant cost-saving measures taken in response to the COVID-19 pandemic. These cost-saving measures were temporary and substantially ~~completed~~ended during the second half of 2020.

The $196.1 million increase in selling, general and administrative expenses within our health care distribution segment for the three months ended June 26, 2021 as compared to the prior year period was attributable to an increase of ~~October~~$186.7 million of operating costs and an increase of $24.4 million of additional costs from acquired companies, partially offset by a decrease of $15.0 million in restructuring costs. The $21.6million increase in selling, general and administrative expenses within our technology and value-added services segment for the three months ended June 26, 2021 as compared to the prior year period was attributable to an increase of $16.2 million of operating costs and an increase of $5.8 million of additional costs from acquired companies, partially offset by a decrease of $0.4 million in restructuring costs. As a percentage of net sales, selling, general and administrative expenses decreased to 22.9% from 27.4% for the comparable prior year period, primarily due to the increased sales base.

As a component of total selling, general and administrative expenses, selling expenses increased $151.3 million, or 58.5% to $409.8 million, for the three months ended June 26, 2021 from the comparable prior year period primarily due to an increase in payroll and payroll related costs. As a percentage of net sales, selling expenses decreased to 13.8% from 15.3% for the comparable prior year period, primarily due to the increased sales base.

Table of Contents

As a component of total selling, general and administrative expenses, general and administrative expenses increased $66.4 million, or 32.7% to $269.6 million, for the three months ended June 26, 2021 from the comparable prior year period, primarily due to an increase in payroll and payroll related costs. As a percentage of net sales, general and administrative expenses decreased to 9.1% from 12.1% for the comparable prior year period, primarily due to the increased sales base.

Other Expense, Net

Other expense, net, for the three months ended June 26, 2021 and June 27, 2020 was as follows (in thousands):

		June 26,		June 27,		Variance
		2021		2020		$		%
Interest income		$	1,357	$	1,997	$	(640)	(32.0)	%
Interest expense			(6,376)		(10,486)		4,110	39.2
Other, net			354		(291)		645	221.6
	Other expense, net	$	(4,665)	$	(8,780)	$	4,115	46.9

Interest income decreased $0.6 million primarily due to lower interest rates and reduced late fee income. Interest expense decreased $4.1 million primarily due to reduced credit line borrowings and lower interest rates on certain of our private placement borrowings.

Income Taxes

For the three months ended June 26, 2021, our effective tax rate was 23.4% compared to 5.9% for the prior year period. The difference between our effective tax rate and the federal statutory tax rate for the three months ended June 26, 2021, was primarily due to state and foreign income taxes, interest expense and tax charges and credits associated with legal entity reorganizations. The difference between our effective tax rate and the federal statutory tax rate for the three months ended June 27, 2020, primarily relates to state and foreign income taxes and a valuation allowance recognized on a portion of a deferred tax asset. Further, our effective tax rate was distorted due to our low pretax loss during the second quarter ended June 27, 2020.

Table of Contents

Six Months Ended June 26, 2021 Compared to Six Months Ended June 27, 2020

Net Sales

Net sales for the six months ended June 26, 2021 and June 27, 2020 were as follows (in thousands):

			June 26,		% of		June 27,		% of		Increase/(Decrease)
			2021		Total		2020		Total		$		%
Health care distribution ⁽¹⁾
	Dental		$	3,699,272	62.8	%	$	2,416,368	58.7	%	$	1,282,904	53.1	%
	Medical			1,897,865	32.2			1,418,498	34.5			479,367	33.8
		Total health care distribution		5,597,137	95.0			3,834,866	93.2			1,762,271	46.0
Technology and value-added services ⁽²⁾				295,047	5.0			237,192	5.8			57,855	24.4
		Total excluding Corporate TSA revenue		5,892,184	100.0			4,072,058	99.0			1,820,126	44.7
Corporate TSA revenue ⁽³⁾				-	-			41,212	1.0			(41,212)	-
		Total	$	5,892,184	100.0	%	$	4,113,270	100.0	%	$	1,778,914	43.2

The 43.2% increase in net sales for the six months ended June 26, 2021 includes an increase of 39.8% in local currency revenue (35.6% increase in internally generated revenue and 4.2% growth from acquisitions) and an increase of 3.4% related to foreign currency exchange. Excluding sales of products under the transition services agreement with Covetrus, our net sales increased 44.7%, including an increase in local currency revenue of 41.2% (37.0% increase in internally generated revenue and 4.2% growth from acquisitions) and an increase of 3.5% related to foreign currency exchange. Sales for the six months ended June 26, 2021 benefited from sales of PPE and COVID-19 related products of approximately $811.7 million, an increase of 125.9% versus the prior year. Excluding PPE and COVID-19 related products, the increase in internally generated local currency sales was 28.8%. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. On a comparable basis to the six months ended June 29, 2019, our net sales for the six months ended June 26, 2021 increased by 16.3% in local currency.

The 53.1% increase in dental net sales for the six months ended June 26, 2021 includes an increase of 47.6% local currency revenue (42.2% increase in internally generated revenue and 5.4% growth from acquisitions) and an increase of 5.5% related to foreign currency exchange. The 47.6% increase in local currency sales was attributable to an increase in dental consumable merchandise revenue of 49.4% (42.7% increase in internally generated revenue and 6.7% growth from acquisitions), and an increase in dental equipment sales and service revenues of 41.1% (40.4% increase in internally generated revenue and 0.7% growth from acquisitions). The COVID-19 pandemic began to adversely impact our worldwide dental revenue beginning in mid-March of 2020 as many dental offices progressively closed or began seeing a limited number of patients. However, in the second half of the quarter ended June 27, 2020 and continuing through the second quarter of 2021 patient traffic levels returned to levels approaching pre-pandemic levels, thus contributing to growth in worldwide dental revenues. Additionally, global dental sales for the six months ended June 26, 2021 benefited from sales of PPE and COVID-19 related products of approximately $351.1 million, an increase of 80.0% versus the prior year. Excluding PPE and COVID-19 related products, the increase in internally generated local currency dental sales was 41.9%. On a comparable basis to the six months ended June 29, 2019, our dental net sales for the six months ended June 26, 2021 increased by 10.7% in local currency.

Table of Contents

The 33.8% increase in medical net sales for the six months ended June 26, 2021 is attributable to an increase of 33.5% local currency growth (31.4% increase in internally generated revenue and 2.1% growth from acquisitions) and an increase of 0.3% related to foreign currency exchange. Economic conditions relating to the COVID-19 pandemic have had less of an impact on the performance of our medical group versus dental, in part due to continued strong sales of PPE, such as masks, gowns and face shields, and other COVID-19 related products, such as diagnostic test kits. Globally, our medical business recorded sales of $460.6 million sales of such PPE and other COVID-19 related products for the six months ended June 26, 2021, an increase of approximately 180.5% compared to the prior year. Excluding sales of PPE and other COVID-19 related products, medical internal sales in local currencies increased by 12.0%. On a comparable basis to the six months ended June 29, 2019, our medical net sales for the six months ended June 26, 2021 increased by 33.3% in local currency.

The 24.4% increase in technology and value-added services net sales for the six months ended June 26, 2021 is attributable to an increase of 22.5% in local currency revenue (16.7% increase in internally generated revenue and 5.8% growth from acquisitions) and 1.9% related to foreign currency exchange. Sales growth was driven by our practice management business, as well as strong financial services revenue, which benefitted from dental equipment sales growth. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which significantly impacted transactional software revenues. On a comparable basis to the six months ended June 29, 2019, our technology and value-added services net sales for the six months ended June 26, 2021 increased by 10.4% in local currency.

Gross Profit

Gross profit and gross margin percentages by segment and in total for the six months ended June 26, 2021 and June 27, 2020 were as follows (in thousands):

		June 26,		Gross		June 27,		Gross		Increase/(Decrease)
		2021		Margin %		2020		Margin %		$		%
Health care distribution		$	1,574,825	28.1	%	$	1,034,358	27.0	%	$	540,467	52.3	%
Technology and value-added services			205,777	69.7			164,768	69.5			41,009	24.9
	Total excluding Corporate TSA revenues		1,780,602	30.2			1,199,126	29.4			581,476	48.5
Corporate TSA revenues			-	-			1,154	2.8			(1,154)	-
	Total	$	1,780,602	30.2		$	1,200,280	29.2		$	580,322	48.3

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology and value-added services segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in research and development.

During December 2020, our previous transition services agreement with Covetrus, in connection with the completion of the Animal-Health Spin-off, concluded. Under this agreement, Covetrus had agreed to purchase certain products from us at a mark-up that ranged from 3% to 6% of our product cost to cover handling costs.

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting our gross profit margin. For example, sales of our private label products achieve gross profit margins that are higher than average. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who normally purchase lower volumes at greater frequencies.

Health care distribution gross profit decreased $6.8 million, or 1.0%, for the three months ended September 26, 2020 compared to the prior year period, due primarily to the COVID-19 pandemic. Health care distribution gross profit margin decreased to 24.4% for the three months ended September 26, 2020 from 28.1% for the comparable prior year period. The overall decrease in our health care distribution gross profit is attributable to an $85.2 million decline in gross profit due to the decrease in the gross margin rates and $1.4 million reduction in gross profit from acquisitions, partially offset by an increase of $77.0 million from internally generated revenue. Gross profit margin was negatively affected by PPE products, primarily due to significant adjustments recorded for PPE inventory and other COVID-19 related products caused by volatility of pricing and demand experienced during the quarter, which conditions may recur and adversely impact gross profit margins in future periods. During the quarter, we continued to earn lower vendor rebates, due to lower purchase volumes, during the year in our health care distribution segment, which also contributes to the lower gross profit margin.

Table of Contents

Health care distribution gross profit increased $540.5 million, or 52.3%, for the six months ended June 26, 2021 compared to the prior year period. Health care distribution gross profit margin increased to 28.1% for the six months ended June 26, 2021 from 27.0% for the comparable prior year period, primarily due to lower adjustments recorded for PPE inventory. Such adjustments to inventory may recur and adversely impact gross profit margins in future periods, although we do not expect further material inventory adjustments in 2021. The increase in the health care distribution gross profit margin is also attributable to an increase in vendor rebates during the first six months of 2021 due to increased purchase volumes. The overall increase in our health care distribution gross profit is attributable to a $445.6 million increase in internally generated revenue, $53.9 million additional gross profit from acquisitions and an increase of $41.0 million in gross profit due to the increase in the gross margin rates.

Technology and value-added services gross profit ~~decreased $0.3~~increased $41.0 million, or ~~0.3%~~24.9%, for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 compared to the prior year period. The overall ~~decrease~~increase in our Technology and value-added services gross profit is attributable to ~~a $0.8~~an increase of $30.4 million ~~decrease~~ in internally generated revenue ~~primarily due to the COVID-19 pandemic~~ and ~~a decrease of $1.3 million from gross margin rates, partially offset by $1.8~~$11.0 million additional gross profit from ~~acquisitions.~~acquisitions, partially offset by a $0.4 million decline in gross profit. Technology and value-added services gross profit margin ~~decreased~~increased to ~~72.5%~~69.7% for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 from ~~73.2%~~69.5% for the comparable prior year ~~period primarily due to a decrease in the volume of our transactional revenue from eClaims and credit card processing.~~period.

Selling, General and Administrative

Selling, general and administrative expenses by segment and in total for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020 were as follows (in thousands):

				% of				% of									% of				% of
		September 26,		Respective		September 28,		Respective		Decrease					June 26,		Respective		June 27,		Respective		Increase
		2020		Net Sales		2019		Net Sales		$		%			2021		Net Sales		2020		Net Sales		$		%
Health care distribution	Health care distribution	$	505,370	18.9	%	$	511,116	21.8	%	$	(5,746)	(1.1)	%	Health care distribution	$	1,195,132	21.4	%	$	912,693	23.8	%	$	282,439	30.9	%
Technology and value-added services	Technology and value-added services		61,258	44.3			62,853	45.8			(1,595)	(2.5)		Technology and value-added services		145,196	49.2			121,155	51.1			24,041	19.8
	Total	$	566,628	20.0		$	573,969	22.9		$	(7,341)	(1.3)		Total	$	1,340,328	22.7		$	1,033,848	25.1		$	306,480	29.6

Selling, general and administrative expenses (including restructuring costs in the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 26,~~June 27, 2020) ~~decreased $7.3~~increased $306.5 million, or ~~1.3%~~29.6%, for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 from the comparable prior year period. In the prior year, there were significant cost-saving measures taken in response to the COVID-19 pandemic. These cost-saving measures were temporary and substantially ended during the second half of 2020.

The ~~$5.7~~$282.4 million ~~decrease~~increase in selling, general and administrative expenses within our health care distribution segment for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 as compared to the prior year period was attributable to ~~a reduction~~an increase of ~~$16.9~~$251.5 million of operating costs ~~primarily as a result~~and an increase of ~~cost-saving measures taken in response to the COVID-19 pandemic, partially offset by increases of $3.6~~$47.8 million of additional costs from acquired companies, ~~and an increase~~partially offset by a decrease of ~~$7.6~~$16.9 million in restructuring costs. The ~~$1.6~~$24.0 million ~~decrease~~increase in selling, general and administrative expenses within our technology and value-added services segment for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 as compared to the prior year period was attributable to ~~a reduction~~an increase of ~~$3.3~~$15.1 million of operating costs ~~primarily as a result of cost-saving measures taken in response to the COVID-19 pandemic, partially offset by~~and an increase of ~~$1.5~~$9.2 million of additional costs from acquired companies, ~~and an increase~~partially offset by a decrease of ~~$0.2~~$0.3 million in restructuring costs. As a percentage of net sales, selling, general and administrative expenses decreased to ~~20.0%~~22.7% from ~~22.9%~~25.1% for the comparable prior year period, primarily due to the cost-saving measures taken in response to the COVID-19 pandemic, partially offset by an increase in restructuring costs. The cost savings achieved from measures taken in response to the COVID-19 pandemic are expected to diminish in future periods as most measures were temporary and ended during the third quarter of 2020.increased sales base.

As a component of total selling, general and administrative expenses, selling expenses ~~decreased $12.6~~increased $164.2 million, or ~~3.5%~~26.0% to ~~$345.7~~$794.5 million, for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 from the comparable prior year period, primarily ~~as a result of cost-saving measures taken~~due to an increase in ~~response to the COVID-19 pandemic.~~payroll and payroll related costs. As a percentage of net sales, selling expenses decreased to ~~12.2%~~13.5% from ~~14.3%~~15.3% for the comparable prior year ~~period.~~period, primarily due to the increased sales base.

As a component of total selling, general and administrative expenses, general and administrative expenses increased ~~$5.3~~$142.3 million, or ~~2.4%~~35.3% to ~~$220.9~~$545.8 million, for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 from the comparable prior year period, primarily due to an increase in ~~restructuring~~payroll and payroll related costs. As a percentage of net sales, general and administrative expenses decreased to ~~7.8%~~9.2% from ~~8.6%~~9.8% for the comparable prior year ~~period.~~period, primarily due to the increased sales base.

Table of Contents

Other Expense, Net

Other expense, net, for the ~~three~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019~~June 27, 2020 was as follows (in thousands):

		September 26,		September 28,		Variance					June 26,		June 27,		Variance
		2020		2019		$		%			2021		2020		$		%
Interest income	Interest income	$	2,294	$	3,943	$	(1,649)	(41.8)	%	Interest income	$	3,340	$	5,187	$	(1,847)	(35.6)	%
Interest expense	Interest expense		(11,111)		(12,373)		1,262	10.2		Interest expense		(12,861)		(18,298)		5,437	29.7
Other, net	Other, net		(1,699)		(177)		(1,522)	(859.9)		Other, net		663		(511)		1,174	229.7
	Other expense, net	$	(10,516)	$	(8,607)	$	(1,909)	(22.2)		Other expense, net	$	(8,858)	$	(13,622)	$	4,764	35.0

Interest income decreased ~~$1.6~~$1.8 million primarily due to lower interest rates and reduced late fee income. Interest expense decreased ~~$1.3~~$5.4 million primarily due to reduced ~~interest expense resulting from decreased~~credit line borrowings ~~under our U.S trade accounts receivable securitization~~ and lower interest rates ~~partially offset by increased borrowings under~~on certain of our ~~bank credit lines. Other, net increased primarily due to certain litigation-related costs.~~private placement borrowings.

Income Taxes

For the ~~three~~six months ended ~~September~~June 26, ~~2020,~~2021, our effective tax rate was ~~16.4%~~24.3% compared to ~~23.5%~~ 24.2% for the prior year period. The difference between our effective tax rate and the federal statutory tax rate for the ~~three~~six months ended ~~September~~June 26, ~~2020,~~2021, was primarily due to ~~a U.S. federal income tax settlement, reached during the third quarter, which lowered income tax expense by approximately $15.6 million, as well as~~ state and foreign income taxes, interest expense and ~~interest.~~tax charges and credits associated with legal entity reorganizations. The difference between our effective tax ~~rate~~rates and the federal statutory tax rate for the ~~three~~six months ended ~~September 28, 2019~~June 27, 2020, primarily relates to state and foreign income taxes, interest expense, tax charges and ~~interest expense.~~credits associated with legal entity reorganizations outside the U.S and a valuation allowance recognized on a portion of a deferred tax asset.

Table of Contents

~~Nine Months Ended September 26, 2020 Compared to Nine Months Ended September 28, 2019~~

~~Net Sales~~

~~Net sales for the nine months ended September 26, 2020 and September 28, 2019 were as follows (in thousands):~~

September 26,

% of

September 28,

% of

Increase/(Decrease)

2020

Total

2019

Total

$

%
Health care distribution ⁽¹⁾

Dental

$
4,066,221

58.5
%

$
4,693,711

64.1
%

$
(627,490)

(13.4)
%

Medical

2,445,644

35.2

2,184,927

29.9

260,717

11.9

Total health care distribution

6,511,865

93.7

6,878,638

94.0

(366,773)

(5.3)

Technology and value-added services ⁽²⁾

375,547

5.4

377,983

5.2

(2,436)

(0.6)

Total excluding Corporate TSA revenue

6,887,412

99.1

7,256,621

99.2

(369,209)

(5.1)

Corporate TSA revenue ⁽³⁾

66,004

0.9

60,241

0.8

5,763

9.6

Total

$
6,953,416

100.0
%

$
7,316,862

100.0
%

$
(363,446)

(5.0)

(1)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)
Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)
Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.

The 5.0% decrease in net sales for the nine months ended September 26, 2020 includes a decrease of 4.4% in local currency revenue (5.1% decrease in internally generated revenue, partially offset by 0.7% growth from acquisitions) and a decrease of 0.6% related to foreign currency exchange. Excluding sales of products under the transition services agreement with Covetrus, our net sales decreased 5.1%, including a decrease in local currency revenue of 4.5% (5.2% decrease in internally generated revenue, partially offset by 0.7% growth from acquisitions) and a decrease of 0.6% related to foreign currency exchange. Sales for the nine months ended September 26, 2020 benefited from an approximate 142% increase in sales of PPE and other COVID-19 related products.

The 13.4% decrease in dental net sales for the nine months ended September 26, 2020 includes a decrease of 12.4% local currency revenue (12.7% decrease in internally generated revenue, partially offset by 0.3% growth from acquisitions) and a decrease of 1.0% related to foreign currency exchange. The 12.4% decrease in local currency sales was attributable to a decrease in dental consumable merchandise revenue of 11.6% (12.0% decrease in internally generated revenue, partially offset by 0.4% growth from acquisitions), and a decrease in dental equipment sales and service revenues of 15.4%, all of which is attributable to a decrease in internally generated revenue. The COVID-19 pandemic began to adversely impact our worldwide dental revenue beginning in mid-March as many dental offices progressively closed or began seeing a limited number of patients. However, in the second half of the quarter ended June 27, 2020 and continuing into the quarter ended September 26, 2020 our dental sales began to improve as dental practices began to resume activities and patient traffic increased. Global dental sales for the nine months ended September 26, 2020 benefited from an approximate 66% increase in sales of PPE.

The 11.9% increase in medical net sales for the nine months ended September 26, 2020 is attributable to an increase of 11.9% local currency growth (10.8% increase in internally generated revenue and 1.1% growth from acquisitions). The COVID-19 pandemic began to adversely impact our medical revenue beginning in mid-March and continuing to a lesser extent into the third quarter, as medical offices began seeing a limited increase in the number of patients. Economic conditions relating to the COVID-19 pandemic have had less of an impact on the performance of our medical group versus dental, in part due to continued strong sales of PPE, such as masks, gowns and face shields, and other COVID-19 related products, such as diagnostic test kits. Globally, our medical business experienced growth of sales of such products during the nine months ended September 26, 2020 by approximately 295% compared to the prior year, and these products are the primary contributor to the increase in sales during this period.

~~Table of Contents~~

The 0.6% decrease in technology and value-added services net sales for the nine months ended September 26, 2020 is attributable to a decrease of 0.6% in local currency revenue (4.2% decrease in internally generated revenue, partially offset 3.6% growth from acquisitions). During the second quarter and continuing into the third quarter, in line with the resumption of dental practice operations, the trend for transactional software revenues improved as more patients visited dental practices worldwide.

Although dental and medical practices continued to re-open globally in the third quarter, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our net sales in future periods.

~~Gross Profit~~

~~Gross profit and gross margin percentages by segment and in total for the nine months ended September 26, 2020 and September 28, 2019 were as follows (in thousands):~~

September 26,

Gross

September 28,

Gross

Increase/(Decrease)

2020

Margin %

2019

Margin %

$

%
Health care distribution

$
1,687,615

25.9
%

$
2,004,126

29.1
%

$
(316,511)

(15.8)
%
Technology and value-added services

265,040

70.6

274,358

72.6

(9,318)

(3.4)

Total excluding Corporate TSA revenues

1,952,655

28.4

2,278,484

31.4

(325,829)

(14.3)

Corporate TSA revenues

1,977

3.0

1,804

3.0

173

9.6

Total

$
1,954,632

28.1

$
2,280,288

31.2

$
(325,656)

(14.3)

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology and value-added services segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in research and development.

~~In connection with the completion of the Animal Health Spin-off (see~~ ~~Note 2-Discontinued Operations~~ of the Notes to the Consolidated Financial Statements included under Item 1 for additional details), we entered into a transition services agreement with Covetrus, pursuant to which Covetrus purchases certain products from us. The agreement provides that these products will be sold to Covetrus at a mark-up that ranges from 3% to 6% of our product cost to cover handling costs. These sales have been substantially completed as of October 2020.

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting our gross profit margin. For example, sales of our private label products achieve gross profit margins that are higher than average. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who normally purchase lower volumes at greater frequencies.

Health care distribution gross profit decreased $316.5 million, or 15.8%, for the nine months ended September 26, 2020 compared to the prior year period, due primarily to the COVID-19 pandemic. Health care distribution gross profit margin decreased to 25.9% for the nine months ended September 26, 2020 from 29.1% for the comparable prior year period. The overall decrease in our health care distribution gross profit is attributable to a $165.7 million decrease in internally generated revenue and a $163.5 million decline in gross profit due to the decrease in the gross margin rates, partially offset by $12.7 million additional gross profit from acquisitions. Gross profit margin was negatively affected by PPE products, primarily due to significant adjustments recorded for PPE inventory and other COVID-19 related products caused by volatility of pricing and demand experienced during the quarter, which conditions may recur and adversely impact gross profit margins in future periods. Gross profit margin was also affected by fixed costs included in cost of goods sold that adversely affect gross margin rates when sales are lower. During the year, we continued to earn lower vendor rebates, due to lower purchase volumes, in our health care distribution segment, which also contributes to the lower gross profit margin.

~~Table of Contents~~

Technology and value-added services gross profit decreased $9.3 million, or 3.4%, for the nine months ended September 26, 2020 compared to the prior year period. The overall decrease in our Technology and value-added services gross profit is attributable to a decrease of $11.5 million in internally generated revenue, primarily due to the COVID-19 pandemic and a $9.0 million decline in gross profit due to the decrease in the gross margin rates, partially offset by $11.2 million additional gross profit from acquisitions. Technology and value-added services gross profit margin decreased to 70.6% for the nine months ended September 26, 2020 from 72.6% for the comparable prior year period primarily due to a decrease in the volume of our transactional revenue from eClaims and credit card processing.

~~Selling, General and Administrative~~

~~Selling, general and administrative expenses by segment and in total for the nine months ended September 26, 2020 and September 28, 2019 were as follows (in thousands):~~

% of

% of

September 26,

Respective

September 28,

Respective

Increase / (Decrease)

2020

Net Sales

2019

Net Sales

$

%
Health care distribution

$
1,418,115

21.8
%

$
1,576,996

22.9
%

$
(158,881)

(10.1)
%
Technology and value-added services

182,414

48.6

181,365

48.0

1,049

0.6

Total

$
1,600,529

23.0

$
1,758,361

24.0

$
(157,832)

(9.0)

Selling, general and administrative expenses (including restructuring costs in the nine months ended September 26, 2020 and September 26, 2020) decreased $157.8 million, or 9.0%, for the nine months ended September 26, 2020 from the comparable prior year period. The $158.9 million decrease in selling, general and administrative expenses within our health care distribution segment for the nine months ended September 26, 2020 as compared to the prior year period was attributable to a reduction of $188.2 million of operating costs, primarily as a result of cost-saving measures taken in response to the COVID-19 pandemic, partially offset by increases of $17.6 million of additional costs from acquired companies and an increase of $11.7 million in restructuring costs. The $1.0million increase in selling, general and administrative expenses within our technology and value-added services segment for the nine months ended September 26, 2020 as compared to the prior year period was attributable to an increase of $9.2 million of additional costs from acquired companies and an increase of $0.3 million in restructuring costs, partially offset by a reduction of $8.5 million of operating costs. As a percentage of net sales, selling, general and administrative expenses decreased to 23.0% from 24.0% for the comparable prior year period. The cost savings achieved from measures taken in response to the COVID-19 pandemic are expected to diminish in future periods as most of these measures were temporary and ended during the third quarter of 2020.

As a component of total selling, general and administrative expenses, selling expenses decreased $104.1 million, or 9.6% to $ 980.9 million, for the nine months ended September 26, 2020 from the comparable prior year period, primarily as a result of cost-saving measures taken in response to the COVID-19 pandemic. As a percentage of net sales, selling expenses decreased to 14.1% from 14.8% for the comparable prior year period.

As a component of total selling, general and administrative expenses, general and administrative expenses decreased $53.7 million, or 8.0% to $ 619.6 million, for the nine months ended September 26, 2020 from the comparable prior year period, primarily as a result of cost-saving measures taken in response to the COVID-19 pandemic. As a percentage of net sales, general and administrative expenses decreased to 8.9% from 9.2% for the comparable prior year period.

Our selling, general and administrative expenses for the nine months ended September 26, 2020 continued to be affected by certain estimates we made due to the adverse business environment brought on by the COVID-19 pandemic. For example, in the quarter ended March 28, 2020 we recorded incremental bad debt reserves of approximately $10 million for our global dental business. As of September 26, 2020, we have retained the $10 million incremental bad debt reserves due to the ongoing uncertainties in the markets we serve.

~~Table of Contents~~

In the quarter ended March 28, 2020, we also recognized a net credit of approximately $17.5 million in stock-based compensation expense during the quarter due to our previous estimate that no performance shares granted in 2018, 2019 or 2020 will ultimately vest. Our assumptions regarding vesting of performance shares under our 2018, 2019 and 2020 LTIP remain largely unchanged from those as of March 28, 2020. Accordingly, we did not recognize any significant stock compensation expense related to performance shares during the nine months ended September 26, 2020.

During the quarter ended March 28, 2020, we recorded total impairment charges of approximately $6.1 million during the quarter related to prepaid royalty expenses and a customer relationship intangible asset.

~~Other Expense, Net~~

~~Other expense, net, for the nine months ended September 26, 2020 and September 28, 2019 was as follows (in thousands):~~

September 26,

September 28,

Variance

2020

2019

$

%
Interest income

$
7,481

$
12,368

$
(4,887)

(39.5)
%
Interest expense

(29,409)

(41,459)

12,050

29.1

Other, net

(2,210)

(2,012)

(198)

(9.8)

Other expense, net

$
(24,138)

$
(31,103)

$
6,965

22.4

Interest income decreased $4.9 million primarily due to lower interest rates and reduced late fee income. Interest expense decreased $12.1 million primarily due to decreased borrowings under our U.S trade accounts receivable securitization and lower interest rates, partially offset by increased borrowings under our bank credit lines.

~~Income Taxes~~

For the nine months ended September 26, 2020, our effective tax rate was 20.0% compared to 23.9% for the prior year period. The difference between our effective tax rate and the federal statutory tax rate for the nine months ended September 26, 2020, was primarily due to a U.S. federal income tax settlement, reached during the third quarter, which lowered income tax expense by approximately $15.6 million, as well as state and foreign income taxes and interest. The difference between our effective tax rate and the federal statutory tax rate for the nine months ended September 28, 2019 primarily relates to state and foreign income taxes and interest expense.

~~Table of Contents~~

Liquidity and Capital Resources

Our principal capital requirements have included funding of acquisitions, purchases of additional noncontrolling interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and repurchases of common stock (which ~~have~~had been temporarily ~~suspended)~~suspended in March of 2020, but were resumed during the three months ended March 27, 2021). Working capital requirements generally result from increased sales, special inventory forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have tended to be stronger during the ~~third and fourth quarters~~second half of the year and special inventory forward buy-in opportunities have been most prevalent just before the end of the year, and have caused our working capital requirements to be higher from the end of the third quarter to the end of the first quarter of the following year.

The pandemic and the governmental responses to it had a material adverse effect on our cash flows in the second ~~quarter.~~quarter of 2020. In the latter half of the second quarter of 2020 and continuing ~~into the third quarter,~~through year-end, dental and medical practices began to re-open worldwide. ~~However,~~During the first half of 2021, patient ~~volumes remain below pre-COVID-19~~traffic levels ~~and certain regions in the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there~~returned to levels approaching pre-pandemic levels. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows ~~in future periods~~ and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.

As part of a broad-based effort to support plans for the long-term health of our business and to strengthen the our financial flexibility, we implemented cost reduction measures that included certain reductions in payroll, substantially decreased capital expenditures, reduced corporate spending and elimination of certain non-strategic targeted expenditures. As our markets have begun to recover we have ended most of those temporary expense-reduction initiatives during the third quarter. As the COVID-19 pandemic continues to unfold, we will continue to evaluate appropriate actions for its business.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt placements. Our ability to generate sufficient cash flows from operations is dependent on the continued demand of our customers for our products and services, and access to products and services from our suppliers.

Our business requires a substantial investment in working capital, which is susceptible to fluctuations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity, special inventory forward buy-in opportunities and our desired level of inventory. We anticipate future increases in our working capital requirements.

We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change our funding structure to reflect any new requirements.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets, and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently foreseeable short-term and long-term capital needs. We have no off-balance sheet arrangements.

On February 7, 2019, we completed the Animal Health Spin-off. On the Distribution Date we received a tax free distribution of $1,120 million from Covetrus, which has been used to pay down our debt, thereby generating additional debt capacity that can be used for general corporate purposes, including share repurchases and mergers and acquisitions.

Net cash from continuing operations provided by operating activities was ~~$248.4~~$221.7 million for the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, compared to net cash from continuing operations ~~provided by~~used in operating activities of ~~$525.2~~$12.8 million for the comparable prior year period. The net change of ~~$276.8~~$234.6 million was primarily attributable to ~~lower~~higher net income, lower distributions from equity affiliates, and increased working capital requirements, specifically an increase in inventories due to stocking of PPE and other COVID-19 related products, and an increase in accounts receivable due to higher third quarter sales volume. These working capital increases were partially offset by greater growth in accounts payable and accrued expenses. The decrease in distributions from equity affiliates is the result of having sold our equity investment in Hu-Friedy Mfg. Co., LLC in the fourth quarter of 2019.income.

~~Table of Contents~~

Net cash from continuing operations used in investing activities was ~~$94.0~~$341.1 million for the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, compared to ~~$691.3~~$69.6 million for the comparable prior year period. The net change of ~~$597.3~~$271.5 million was ~~primarily~~ attributable to ~~decreased~~increased payments for equity investments and business acquisitions.

Net cash from continuing operations ~~provided by~~used in financing activities was ~~$264.4~~$139.4 million for the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, compared to net cash provided by financing activities of ~~$176.1~~$262.1 million for the comparable prior year period. The net change of ~~$88.3~~$401.5 million was primarily due to ~~increased~~decreased net proceeds from bank borrowings and ~~lower~~increased repurchases of ~~our~~ common ~~stock, partially offset by proceeds received during the prior year related to the Animal Health Spin-off.~~stock.

Table of Contents

The following table summarizes selected measures of liquidity and capital resources (in thousands):

			September 26,		December 28,				June 26,		December 26,
			2020		2019				2021		2020
Cash and cash equivalents	Cash and cash equivalents		$	533,495	$	106,097	Cash and cash equivalents		$	167,228	$	421,185
Working capital⁽¹⁾	Working capital⁽¹⁾			1,265,443		1,188,133	Working capital⁽¹⁾			1,648,607		1,508,313

Debt:	Debt:						Debt:
	Bank credit lines		$	507,372	$	23,975	Bank credit lines		$	72,105	$	73,366
	Current maturities of long-term debt			110,015		109,849	Current maturities of long-term debt			9,839		109,836
	Long-term debt			515,357		622,908	Long-term debt			706,487		515,773
		Total debt	$	1,132,744	$	756,732		Total debt	$	788,431	$	698,975

Leases:	Leases:						Leases:
	Current operating lease liabilities		$	62,914	$	65,349	Current operating lease liabilities		$	75,008	$	64,716
	Non-current operating lease liabilities			200,611		176,267	Non-current operating lease liabilities			243,232		238,727

(1)	Includes $0 million and $127 million of accounts receivable which serve as security for U.S. trade accounts receivable securitization at September 26, 2020 and December 28, 2019 respectively.						At June 26, 2021 and December 26, 2020, there were no trade accounts receivable that were restricted to settle obligations of this VIE, nor were there liabilities of the VIE where the creditors have recourse to us.

Our cash and cash equivalents consist of bank balances and investments in money market funds representing overnight investments with a high degree of liquidity.

Accounts receivable days sales outstanding and inventory turns

Our accounts receivable days sales outstanding from operations ~~increased~~decreased to ~~48.8~~42.3 days as of ~~September~~June 26, ~~2020~~2021 from ~~45.3~~52.4 days as of ~~September 28, 2019.~~June 27, 2020. During the ~~nine~~six months ended ~~September~~June 26, ~~2020,~~2021, we wrote off approximately ~~$5.0~~$4.6 million of fully reserved accounts receivable against our trade receivable reserve. Our inventory turns from operations ~~decreased~~increased to ~~4.7~~5.1 as of ~~September~~June 26, ~~2020~~2021 from ~~4.9~~4.2 as of ~~September 28, 2019.~~June 27, 2020. Our working capital accounts may be impacted by current and future economic conditions.

Bank Credit Lines

Bank credit lines consisted of the following:

		September 26,		December 28,			June 26,		December 26,
		2020		2019			2021		2020
Revolving credit agreement	Revolving credit agreement	$	-	$	-	Revolving credit agreement	$	-	$	-
364-day credit agreement			500,000		-
Other short-term bank credit lines	Other short-term bank credit lines		7,372		23,975	Other short-term bank credit lines		72,105		73,366
Total	Total	$	507,372	$	23,975	Total	$	72,105	$	73,366

~~The increase in the level of borrowings under our bank credit lines as of September 26, 2020 was attributable to potential cash requirements due to the impact of the COVID-19 pandemic.~~

~~Table of Contents~~

Revolving Credit Agreement

On April 18, 2017, we entered into a $750 million revolving credit agreement (the “Credit Agreement”), which matures in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. We expect ~~the~~most LIBOR ~~rate~~rates to be discontinued ~~at some point during~~immediately after December 31, 2021, while the remaining LIBOR rates will be discontinued immediately after June 30, 2023, which will require an amendment to our debt agreements to reflect a new reference rate. We do not expect the discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our financial position or to materially affect our interest expense. The Credit Agreement also requires, among other things, that we maintain maximum leverage ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of ~~September~~June 26, 2021, and December 26, 2020, ~~and December 28, 2019, the~~we had no borrowings onunder this revolving credit ~~facility~~facility. As of June 26, 2021, and December 26, 2020, there were ~~$0.0~~$9.3 million and ~~$0.0 million, respectively. As of September 26, 2020 and December 28, 2019, there were~~ $9.5 ~~million and $9.6~~ million of letters of credit, respectively, provided to third parties under the credit facility.

Table of Contents

364-Day Credit Agreement

On ~~April 17, 2020,~~March 4, 2021, we ~~entered into a new~~repaid the outstanding obligations and terminated the lender commitments under our $700 million 364-day credit agreement ~~with JPMorgan Chase Bank, N.A. and U.S. Bank National Association as joint lead arrangers and joint bookrunners.~~which was entered into on April 17, 2020. This facility ~~matures~~was originally scheduled to mature on April 16, 2021. As of September 26, 2020, the borrowings on this credit facility were $500 million. We have the ability to borrow the remaining $200 million on a revolving basis as needed, subject to the terms and conditions of the credit agreement. The interest rate for borrowings under this facility will fluctuate based on our net leverage ratio. At September 26, 2020, the interest rate on this facility was 2.81%. The proceeds from this facility can be used for working capital requirements and general corporate purposes, including, but not limited to, permitted refinancing of existing indebtedness.

Other Short-Term Credit Lines

As of ~~September~~June 26, ~~2020~~2021 and December ~~28, 2019,~~26, 2020, we had various other short-term bank credit lines available, of which ~~$7.4~~$72.1 million and ~~$24~~$73.4 million, respectively, were outstanding. At ~~September~~June 26, ~~2020~~2021 and December ~~28, 2019,~~26, 2020, borrowings under all of these credit lines had a weighted average interest rate of ~~2.82%~~5.98% and ~~3.45%~~4.14%, respectively.

~~Table of Contents~~

Long-term debt

Long-term debt consisted of the following:

		September 26,		December 28,			June 26,		December 26,
		2020		2019			2021		2020
Private placement facilities	Private placement facilities	$	613,549	$	621,274	Private placement facilities	$	706,332	$	613,498
U.S. trade accounts receivable securitization			-		100,000
Note payable due in 2025 with an interest rate of 3.1%
	at September 26, 2020		1,438		-
Note payable						Note payable		-		1,554
Various collateralized and uncollateralized loans payable with interest,	Various collateralized and uncollateralized loans payable with interest,					Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2023 at interest rates					in varying installments through 2023 at interest rates
	ranging from 2.62% to 4.22% at September 26, 2020 and					ranging from 2.45% to 4.27% at June 26, 2021 and
	ranging from 2.56% to 10.5% at December 28, 2019		4,273		6,089	ranging from 2.62% to 4.27% at December 26, 2020		4,293		4,596
Finance lease obligations (see Note 7)			6,112		5,394
Finance lease obligations (see Note 6)						Finance lease obligations (see Note 6)		5,701		5,961
	Total		625,372		732,757	Total		716,326		625,609
Less current maturities	Less current maturities		(110,015)		(109,849)	Less current maturities		(9,839)		(109,836)
	Total long-term debt	$	515,357	$	622,908	Total long-term debt	$	706,487	$	515,773

Table of Contents

Private Placement Facilities

~~On September 15, 2017, we increased our available~~Our private placement facilities, with three insurance companies, tohave a total facility amount of $1 ~~billion. On June 23, 2020, the expiration date for our private placement facilities was extended through June 23, 2023. These facilities~~billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through June 23, 2023. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. On June 29, 2018, we amended and restated the above private placement facilities to, among other things, (i) permit the consummation of the Animal Health Spin-off and (ii) provide for the issuance of notes in Euros, British Pounds and Australian Dollars, in addition to U.S. Dollars. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

On ~~June 23, 2020,~~March 5, 2021, we amended the private placement facilities to, among other things, ~~(i) temporarily~~(a) modify the financial covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum maintenance total leverage ratio to ~~net leverage ratio until March 31, 2021, (ii) increase~~3.25x and remove the ~~maximum maintenance leverage ratio through March 31, 2021, but with a~~ 1.00% interest rate increase ~~on the outstanding notes~~triggered if the net leverage ratio exceeds 3.0x, which will remain in effect until we deliver financials for a four-quarter period ending on or after June 30, 2021 showing compliance with the total leverage ratio requirement, and (iii) make certain other changes conformingwere to ~~the Credit Agreement, dated as of April 18, 2017.~~exceed 3.0x.

~~Table of Contents~~

The components of our private placement facility borrowings as of ~~September~~June 26, ~~2020~~2021 are presented in the following table (in thousands):


		Amount of						Amount of
		Borrowing		Borrowing				Borrowing		Borrowing
Date of Borrowing		Outstanding		Rate		Due Date		Outstanding		Rate		Due Date
January 20, 2012⁽¹⁾		$	14,286	3.09	%	January 20, 2022		$	7,143	3.09	%	January 20, 2022
January 20, 2012			50,000	3.45		January 20, 2024			50,000	3.45		January 20, 2024
December 24, 2012			50,000	3.00		December 24, 2024			50,000	3.00		December 24, 2024
June 2, 2014			100,000	3.19		June 2, 2021
June 16, 2017			100,000	3.42		June 16, 2027			100,000	3.42		June 16, 2027
September 15, 2017			100,000	3.52		September 15, 2029			100,000	3.52		September 15, 2029
January 2, 2018			100,000	3.32		January 2, 2028			100,000	3.32		January 2, 2028
September 2, 2020⁽²⁾			100,000	2.35		September 3, 2030
September 2, 2020									100,000	2.35		September 2, 2030
June 2, 2021									100,000	2.48		June 2, 2031
June 2, 2021									100,000	2.58		June 2, 2033
Less: Deferred debt issuance costs			(737)						(811)
		$	613,549					$	706,332

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.	(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.						(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.
(2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030.

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. Our current facility, which has a purchase limit of $350 million, was scheduled to expire on April 29, 2022. On June 22, 2020, the expiration date for this facility was extended to June 12, ~~2023.~~2023 and was amended to adjust certain covenant levels for 2020. As of ~~September~~June 26, 2021 and December 26, 2020, ~~and December 28, 2019, the~~there were no borrowings outstanding under this securitization facility. At June 26, 2021, the interest rate on borrowings under this facility ~~were $0 million and $100 million, respectively.~~was based on the asset-backed commercial paper rate of 0.14% plus 0.95%, for a combined rate of 1.09%. At ~~September~~December 26, 2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.22% plus 0.95%, for a combined rate of 1.17%~~. At December 28, 2019, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 1.90% plus 0.75%, for a combined rate of 2.65%~~.

If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of 25 to 45 basis points depending upon program utilization.

~~Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance sheets.~~

~~On June 22, 2020 we amended this facility to adjust certain covenant levels, in particular for the second and third quarters of 2020.~~

Table of Contents

Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles, and certain equipment. Our leases have remaining terms of less than one year to approximately 1615 years, some of which may include options to extend the leases for up to 10 years. As of ~~September~~June 26, ~~2020,~~2021, our right-of-use assets related to operating leases were ~~$249.9~~$301.4 million and our current and non-current operating lease liabilities were ~~$62.9~~$75 million and ~~$200.6~~$243.2 million, respectively.

56
Stock Repurchases

~~Table of Contents~~

~~Stock Repurchases~~On March 8, 2021, we announced the reinstatement of our share repurchase program.

From March 3, 2003 through ~~September~~June 26, ~~2020,~~2021, we repurchased ~~$3.6~~$3.8 billion, or ~~75,563,289~~78,430,846 shares, under our common stock repurchase programs, with ~~$201.2~~$400.0 million available as of ~~September~~June 26, ~~2020~~2021 for future common stock share repurchases.

As a result of the COVID-19 pandemic, as previously announced, we have temporarily suspended our share repurchase program in an effort to preserve cash and exercise caution during this uncertain period and due to certain restrictions related to financial covenants in our credit facilities.

Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and the year ended December ~~28, 2019~~26, 2020 are presented in the following table:

		September 26,		December 28,			June 26,		December 26,
		2020		2019			2021		2020
Balance, beginning of period	Balance, beginning of period	$	287,258	$	219,724	Balance, beginning of period	$	327,699	$	287,258
Decrease in redeemable noncontrolling interests due to	Decrease in redeemable noncontrolling interests due to					Decrease in redeemable noncontrolling interests due to
	redemptions		(12,636)		(2,270)	redemptions		(1,130)		(17,241)
Increase in redeemable noncontrolling interests due to business	Increase in redeemable noncontrolling interests due to business					Increase in redeemable noncontrolling interests due to business
	acquisitions		25,955		74,865	acquisitions		140,155		28,387
Net income attributable to redeemable noncontrolling interests	Net income attributable to redeemable noncontrolling interests		7,253		14,838	Net income attributable to redeemable noncontrolling interests		14,033		13,363
Dividends declared	Dividends declared		(7,272)		(10,264)	Dividends declared		(9,954)		(12,631)
Effect of foreign currency translation loss attributable to
Effect of foreign currency translation gain (loss) attributable to						Effect of foreign currency translation gain (loss) attributable to
	redeemable noncontrolling interests		(10,999)		(2,335)	redeemable noncontrolling interests		570		(4,279)
Change in fair value of redeemable securities	Change in fair value of redeemable securities		5,141		(7,300)	Change in fair value of redeemable securities		132,708		32,842
Balance, end of period	Balance, end of period	$	294,700	$	287,258	Balance, end of period	$	604,081	$	327,699

Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a floor amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

Additionally, some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 and ~~September 28, 2019,~~June 27, 2020, there were no material adjustments recorded in our consolidated statements of income relating to changes in estimated contingent purchase price liabilities.

Noncontrolling Interests

Noncontrolling interests represent our less than 50% ownership interest in an acquired subsidiary. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests.

5752

Table of Contents

Critical Accounting Policies and Estimates

There have been no material changes in our critical accounting policies and estimates from those disclosed in Item 7 of our Annual Report on Form 10-K for the year ended December ~~28, 2019,~~26, 2020, except accounting policies adopted as of December ~~29, 2019,~~27, 2020, which are discussed in Note ~~3-Critical~~2-Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards of the Notes to the Consolidated Financial Statements included under Item 1.

Our financial results for the ~~nine~~six months ended ~~September 26,~~June 27, 2020 were affected by certain estimates we made due to the adverse business environment brought on by the COVID-19 pandemic. For example, in the quarter ended March 28, 2020 we recorded incremental bad debt reserves of approximately $10.0 million for our global dental ~~business and continued to retain those incremental reserves through the quarter ended September 26, 2020.~~business. During the quarter ended March 28, 2020, we also recognized a net credit of approximately $17.5 million in stock-based compensation expense due to our estimate that no performance shares granted in 2018, 2019 or 2020 ~~will~~would ultimately vest. For the quarter ended ~~September 26,~~June 27, 2020, we continued to estimate that no such performance-based shares ~~will~~would ultimately vest. In contrast, for the six months ended June 26, 2021, we recorded $30.2 million in stock-based compensation. Additionally, in the quarter ended March 28, 2020, we recorded total impairment charges of approximately $6.1 million related to prepaid royalty expenses and a customer relationship intangible asset. We had no material impairment charges in the quarter ended ~~September~~June 26, ~~2020.~~2021. Although our selling, general and administrative expenses for the ~~nine~~six months ended ~~September~~June 26, ~~2020~~2021 represent management's best estimates and assumptions that affect the reported amounts, our judgment could change in the future due to the significant uncertainty surrounding the macroeconomic effect of the COVID-19 pandemic.

Accounting Standards Update

For a discussion of accounting standards updates that have been adopted or will be adopted, see Note ~~3-Critical~~2-Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards of the Notes to the Consolidated Financial Statements included under Item 1.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk from that disclosed in Item 7A of our Annual Report on Form 10-K for the year ended December ~~28, 2019.~~26, 2020.

5853

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of ~~September~~June 26, ~~2020~~2021, to ensure that all material information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and that all such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

The combination of acquisitions, continued acquisition integrations and system ~~implementations~~implementation undertakenduring the quarter and carried over from prior quarters, as well as changes to the operating methods of some of our internal controls over financial reporting due to the COVID-19 pandemic, when considered in the aggregate, represents a material change in our internal control over financial reporting.

During the quarter ended ~~September~~June 26, ~~2020,~~2021, we completed acquisitions of a technology and value added-services business and a dental business with combined aggregate annual revenues of approximately $60 million. In addition, post-acquisition integration related activities continued for our ~~global~~medical and dental ~~and North American medical~~ businesses acquired during prior quarters, representing aggregate annual revenues of approximately ~~$345~~$600 million. These acquisitions, the majority of which utilize separate information and financial accounting systems, have been included in our consolidated financial statements since their respective dates of acquisition.

Also, during the quarter ended ~~September~~June 26, ~~2020,~~2021, we completed ~~the~~ systems implementation activities ~~related~~ to ~~a new CRM~~upgrade the equipment system for aour U.S. ~~technology business having approximate~~dental and medical businesses representing aggregate projected annual revenues of ~~$216~~approximately $960 million.

All acquisitions, continued acquisition integrations and system ~~implementations~~implementation involve necessary and appropriate change-management controls that are considered in our quarterly assessment of the design and operating effectiveness of our internal control over financial reporting.

In addition, as a result of a combination of continued governmental imposed and Company directed closures of some of our facilities due to the COVID-19 pandemic, we have had to maintain a number of changes to the operating methods of some of our internal controls. For example, moving from manual sign-offs and in-person meetings to electronic sign-offs and electronic communications such as email and telephonic or video conference due to out-of-office working arrangements. However, the design of our internal control framework and objectives over financial reporting remains unchanged and we do not believe that these changes have materially affected, or are reasonably likely to materially affect, the effectiveness of our internal control over financial reporting.

Limitations of the Effectiveness of Internal Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

5954

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

For a discussion of Legal Proceedings, see Note ~~18–~~17–Legal Proceedings of the Notes to the Consolidated Financial Statements included under Item 1.

ITEM 1A. RISK FACTORS

~~In addition to~~There have been no material changes from the ~~other information set forth~~risk factors disclosed in ~~this report, you should carefully consider the factors discussed in~~Part 1, Item ~~1A. "Risk factors" in~~1A, of our Annual Report on Form 10-K for the year ended December ~~28, 2019. We provide an update to the following risk factor.~~26, 2020.

The recent COVID-19 pandemic and the responses of governments to it had, and may again have, a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. In the future, our business, results of operations, cash flows, financial condition and liquidity may be negatively impacted by the effects of other disease outbreaks, epidemics, pandemics, or similar wide spread public health concerns and other natural disasters.

The COVID-19 pandemic has had, and continues to have, an unprecedented impact on society, worldwide economic activity, and the health care sector (particularly, the dental market). As a global healthcare solutions company, the COVID-19 pandemic and the governmental responses to it had, and may again have, a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. In March and April 2020, the dental market was severely impacted by COVID-19, with many, if not a majority, of practices being closed or open on a limited basis only. Although dental practice openings and patient volume recovery in the United States and many other countries have rebounded faster than originally anticipated, they still remain below pre-COVID-19 levels, material uncertainty remains and the potential for one or more significant resurgences of COVID-19 could cause a significant reduction in dental practice openings and patient volume recovery, or further delay the return to normal operations. Even after COVID-19 has subsided, we may continue to experience material adverse impacts to our business, results of operations and cash flows as a result of, among other things, its global economic impact, including any recession that has occurred or may occur in the future, or a prolonged period of economic slowdown or the reluctance of patients to return for elective dental or medical care.

~~The impacts and potential impacts from the COVID-19 pandemic include, but are not limited to:~~

• ~~Significant reductions in demand or significant volatility in demand for certain of our products.~~ For example, in March and April 2020, many dental offices in the United States performed only emergency procedures, and rescheduled wellness exams and elective procedures. Dental offices in other countries also have experienced closures or restricted operations, as have medical offices around the world. Such closures and restrictions impacted our customers’ spending with us and had, and if reinstated may again have, a material adverse effect on our business, results of operations and cash flows. Although dental practice openings and patient volume recovery have rebounded faster than originally anticipated, capacity constraints in offices and demand-side factors may again lead to reductions in demand or significant volatility in demand for our products. Additionally, significant reduction in demand for certain of our products or customers’ decisions to delay the purchase of large equipment may result in us having increased inventory;

• ~~Shortage of Certain Personal Protective Equipment (PPE~~). Supply chain disruptions for PPE and an increased demand for these products has resulted, and may continue to result, in backorders of certain PPE and a potential scarcity in raw materials to make certain PPE. Prices for certain PPE have been volatile. Although we have expanded our sourcing in critical product categories, added substitute products, and adapted our transportation model to shorten lead-times in product delivery, among other improvements, we still may not be able to supply our customers with the quantity of certain PPE products they demand, which may lead to our customers seeking alternative sources of supply. Furthermore, healthcare professionals’ inability to obtain a sufficient quantity of certain PPE from us and other suppliers could limit capacity at such offices, which could again result in material

~~Table of Contents~~

adverse impacts on our business, results of operations and cash flows, and could materially adversely affect our financial condition and liquidity. Conversely, we recorded significant charges in the third quarter for PPE inventory due to volatility of pricing for PPE, and, depending upon the course of the pandemic, if PPE pricing or demand decreases, our margins and the value of certain our PPE inventory could be further negatively impacted in future periods, which could result in a material adverse impact on our business, results of operations and cash flows;

• ~~Reduction in Peoples’ Ability and Willingness to be in Public.~~ Although some restrictions recommended by several public health organizations, and implemented by many local governments, to slow and limit the transmission of COVID-19 (including business closures and restrictions, stay-at-home and similar measures) have been lifted or partially lifted, ongoing social distancing ordinances and similar restrictions, and the potential for one or more significant resurgences of COVID-19 may result in the re-imposition of governmental social distancing and other restrictions, and/or cause people to be less willing to go to elective medical and dental appointments, which could again materially adversely affect demand for our products. A lengthened period of materially suppressed demand could again cause material adverse impacts on our business, results of operations and cash flows and could materially adversely affect our financial condition and liquidity;

• ~~Potential delays in customer payments, or defaults on our customer credit arrangements.~~ We generally sell products to customers with payment terms. If customers’ cash flows or operating and financial performance deteriorate, or if they are unable to make scheduled payments or obtain credit, they may not be able to pay, or may delay payment to us. Likewise, for similar reasons, suppliers may restrict credit or impose more stringent payment terms. The inability of current and/or potential customers to pay us for our products and/or services or any demands by suppliers for more stringent payment terms may materially adversely affect our business, results of operations, cash flows, financial condition and liquidity and may limit the amounts we can borrow under our trade accounts receivable securitization;

• ~~Impact on third parties’ ability to meet their obligations to us; impact on our ability to meet obligations to third parties.~~ Failure of third parties on which we rely, including our suppliers, contract manufacturers, distributors, contractors (including third party shippers), banks, joint venture partners and external business partners, to meet their obligations to us, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties, or by travel restrictions and border closures, may materially adversely affect our business, results of operations, cash flows, financial condition and liquidity. Certain of our contracts with supply partners contain minimum purchase requirements or include rebate provisions if we satisfy certain sales or purchasing targets that, in certain cases we have not been able to satisfy and in other cases we may not be able to fully satisfy, due to the impact of the COVID-19 pandemic. Rebate income recognized to date this year is less than rebates earned over the same period last year. Our failure to satisfy such contractual provisions or renegotiate more favorable terms could materially adversely affect our business, results of operations and cash flows;

• ~~Negative impact on our workforce and impact of adapted business practices.~~ The spread of COVID-19 has caused us to implement temporary cost reduction measures (including a payroll cost reduction plan centered around furloughs, reduced pay and work hours, voluntary unpaid time off, suspension of the 401(k) match, and job reductions), most of which have now ended, modify our business practices (including employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees. As the COVID-19 pandemic continues to unfold, we will continue to evaluate appropriate actions for our business. Many of our employees shifted abruptly to working remotely and continue to do so. An extended period of modified pay and business practices and remote work arrangements could have a negative impact on employee morale, strain our business continuity plans, introduce operational risk (including but not limited to cybersecurity risks), and impair our ability to efficiently operate our business;

• ~~Significant changes in political conditions.~~ Significant changes in political conditions in markets in which we purchase and distribute our products have occurred and are expected to continue at least during the pendency of the pandemic, including quarantines, governmental or regulatory actions, closures or other restrictions that limit or close our operating facilities, restrict our employees’ ability to travel or perform necessary business functions, or

~~Table of Contents~~

otherwise constrain the operations of our business partners, suppliers, or customers, which may materially adversely affect our business, results of operations, cash flows, financial condition and liquidity;

• ~~Potential impact on our ability to meet obligations under credit facilities.~~ Although we recently entered into amendments to our material credit facilities to, among other things, extend the maturity dates and temporarily provide additional flexibility under certain covenants, an extended negative impact of COVID-19 on our business, results of operations, cash flows, financial condition and liquidity could impact our ability to meet our obligations under credit facilities or outstanding long term debt, which contain maximum leverage ratios, and customary representations, warranties and affirmative covenants;

• ~~Volatility in the financial markets.~~ ~~Volatility in the financial markets may materially adversely affect the availability and cost of credit to us;~~

• ~~Refocusing management resources to mitigate effects of COVID-19~~. Our management is focused on mitigating the effects of COVID-19, which has required, and may continue to require for the duration of the pandemic, a large investment of time and resources across the Company, and may delay certain strategic and other plans which could materially adversely affect our business;

• ~~Potentialincreased costs associated with our self-insured medical insurance programs.~~ We may incur significant employee health care costs under our self-insurance medical insurance programs if a large number of our employees and/or their covered family members become ill from COVID-19; and

• ~~Reputational risk associated with response to COVID-19.~~ If we do not respond appropriately to the COVID-19 pandemic, or if customers do not perceive our response to be adequate, we could suffer damage to our reputation and our brands, which could materially adversely affect our business.

The impact of COVID-19 may also exacerbate other risks discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 28, 2019, any of which could have a material adverse effect on us.

More generally, in the future our business, results of operations, cash flows, financial condition and liquidity may be negatively impacted by the effects of other disease outbreaks, epidemics, pandemics, similar wide spread public health concerns, and other natural disasters.

~~Table of Contents~~

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of equity securities by the issuer

Our share repurchase program announced on March 3, 2003, originally allowed us to repurchase up to two million shares pre-stock splits (eight million shares post-stock splits) of our common stock, which represented approximately 2.3% of the shares outstanding at the commencement of the program. ~~As summarized in the table below, subsequent~~Subsequent additional increases totaling $3.7 billion, authorized by our Board of Directors, to the repurchase program provide for a total of $3.8 billion of shares of our common stock to be repurchased under this program.

Date of

Amount of Additional

Authorization

Repurchases Authorized

June 21, 2004

$
100,000,000

October 31, 2005

100,000,000

March 28, 2007

100,000,000

November 16, 2010

100,000,000

August 18, 2011

200,000,000

April 18, 2012

200,000,000

November 12, 2012

300,000,000

December 9, 2013

300,000,000

December 4, 2014

300,000,000

November 30, 2015

400,000,000

October 18, 2016

400,000,000

September 15, 2017

400,000,000

December 12, 2018

400,000,000

October 30, 2019

400,000,000

On March 8, 2021, we announced the reinstatement of our share repurchase program.

As of ~~September~~June 26, ~~2020,~~2021, we had repurchased approximately ~~$3.6~~$3.8 billion of common stock ~~(75,563,289~~(78,430,846 shares) under these initiatives, with ~~$201.2~~$400.0 million available for future common stock share repurchases.

~~As a result~~The following table summarizes repurchases of ~~the COVID-19 pandemic, as previously announced, we have temporarily suspended~~ our ~~share~~common stock under our stock repurchase program ~~in an effort to preserve cash and exercise caution in this uncertain period and due to certain restrictions related to financial covenants in our credit facilities.~~

~~During~~during the fiscal quarter ended ~~September~~June 26, 2020, we did not make any repurchases of our common stock. The maximum number of shares that could be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time. The maximum number of shares that could be repurchased as of August 1, 2020, August 29, 2020, and September 26, 2020 were 2,927,561, 3,028,466 and 3,422,542, respectively.2021.

~~ITEM 5. OTHER INFORMATION~~

On October 29, 2020, the Compensation Committee of the Board of Directors approved an amendment to the Henry Schein, Inc. Supplemental Executive Retirement Plan (“SERP”), which reinstates our ability to make book-entry contributions to the SERP in the contribution percentage designated by the Compensation Committee, effective as of January 1, 2021. Our executive officers are eligible to participate in the SERP.

~~The above summary is qualified in its entirely by reference to the full text of the SERP amendment, which is attached hereto as Exhibit 10.2 and incorporated herein by reference.~~

				Total Number	Maximum Number
	Total			of Shares	of Shares
	Number	Average		Purchased as Part	that May Yet
	of Shares	Price Paid		of Our Publicly	Be Purchased Under
Fiscal Month	Purchased (1)	Per Share		Announced Program	Our Program (2)
3/28/21 through 4/24/2021	744,696	$	69.25	744,696	6,210,991
4/25/21 through 5/29/2021	528,823		75.98	528,823	5,533,921
5/30/21 through 6/26/2021	268,796		77.38	268,796	5,332,623
	1,542,315			1,542,315


(1) All repurchases were executed in the open market under our existing publicly announced authorized program.

(2) The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time. This table excludes shares withheld from employees to satisfy minimum tax withholding requirements for equity-based transactions.

6355

Table of Contents

ITEM 6. EXHIBITS

~~Exhibits.~~

	~~10.1~~3.1	Third Amended and Restated By-laws of Henry Schein, Inc. ~~2020 Recovery Performance Plan.~~, effective May 13, 2021. (Incorporated by reference to Exhibit ~~10.1~~3.1 to our Current Report on Form 8-K filed on ~~August 12, 2020.~~May 17, 2021.)**
	~~10.2~~	~~Amendment Number Three to the Henry Schein, Inc. Supplemental Executive Retirement Plan, amended and restated effective as of January 1, 2014.**+~~
	31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
	31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
	32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.+
	101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document+
	101.SCH	Inline XBRL Taxonomy Extension Schema Document+
	101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document+
	101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document+
	101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document+
	101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document+
	104	The cover page of Henry Schein, Inc.’s Quarterly Report on Form 10-Q for the quarter ended ~~September~~June 26, ~~2020,~~2021, formatted in Inline XBRL (included within Exhibit 101 attachments).+

+ Filed or furnished herewith.

** Indicates management contract or compensatory plan or agreement.

6456

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	Henry Schein, Inc.
	(Registrant)


	By: /s/ Steven Paladino
	Steven Paladino
	Executive Vice President and
	Chief Financial Officer
	(Authorized Signatory and Principal Financial
	and Accounting Officer)

Dated: ~~November 2, 2020~~August 3, 2021

6557

			February 7,		December 29,
			2019		2018


Cash and cash equivalents			$	6,815	$	23,324
Accounts receivable, net				432,812		434,935
Inventories, net				536,637		555,230
Prepaid expenses and other				120,546		69,525
		Total current assets of discontinued operations		1,096,810		1,083,014
Property and equipment, net				69,790		68,177
Operating lease right-of-use asset, net				57,012		0
Goodwill				742,931		739,266
Other intangibles, net				205,793		208,213
Investments and other				120,518		118,003
		Total long-term assets of discontinued operations		1,196,044		1,133,659
Total assets of discontinued operations			$	2,292,854	$	2,216,673

Accounts payable			$	316,162	$	441,453
Current maturities of long-term debt				657		675
Operating lease liabilities				18,951		0
Accrued expenses:
	Payroll and related			36,847		36,888
	Taxes			24,060		17,552
	Other			80,400		81,039
		Total current liabilities of discontinued operations		477,077		577,607
Long-term debt				1,176,105		23,529
Deferred income taxes				17,019		4,352
Operating lease liabilities				38,668		0
Other liabilities				29,209		34,572
		Total long-term liabilities of discontinued operations		1,261,001		62,453
Total liabilities of discontinued operations			$	1,738,078	$	640,060
Redeemable noncontrolling interests			$	28,270	$	92,432

	Time-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,417	$	58.72
Granted	379		60.02
Vested	(297)		65.93
Forfeited	(47)		59.87
Outstanding at end of period	1,452	$	57.55	$	58.79

	Performance-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,459	$	61.41
Granted	(1,092)		55.89
Vested	(326)		67.51
Forfeited	(40)		57.84
Outstanding at end of period	1	$	52.10	$	58.79

Date of	Amount of Additional
Authorization	Repurchases Authorized
June 21, 2004	$	100,000,000
October 31, 2005		100,000,000
March 28, 2007		100,000,000
November 16, 2010		100,000,000
August 18, 2011		200,000,000
April 18, 2012		200,000,000
November 12, 2012		300,000,000
December 9, 2013		300,000,000
December 4, 2014		300,000,000
November 30, 2015		400,000,000
October 18, 2016		400,000,000
September 15, 2017		400,000,000
December 12, 2018		400,000,000
October 30, 2019		400,000,000